Nuclear	B-protein
factor	I-protein
kappa	I-protein
B	I-protein
activates	O
proenkephalin	O
transcription	O
in	O
T	B-cell_type
lymphocytes	I-cell_type
.	O

Upon	O
activation	O
,	O
T	B-cell_type
lymphocytes	I-cell_type
accumulate	O
high	O
levels	O
of	O
the	O
neuropeptide	O
enkephalin	O
which	O
correlate	O
with	O
high	O
levels	O
of	O
proenkephalin	B-RNA
mRNA	I-RNA
in	O
the	O
cells	O
.	O

Here	O
we	O
investigated	O
the	O
transcriptional	O
basis	O
for	O
these	O
changes	O
.	O

The	O
proenkephalin	O
promoter	O
contains	O
a	O
sequence	O
GGGGACGTCCCC	O
,	O
named	O
B2	B-DNA
,	O
which	O
is	O
similar	O
to	O
the	O
kappa	B-DNA
B	I-DNA
sequence	I-DNA
GGGGACTTTCC	O
,	O
the	O
binding	O
site	O
of	O
the	O
transcription	B-protein
factor	I-protein
nuclear	B-protein
factor	I-protein
(	I-protein
NF	I-protein
)	I-protein
-kappa	I-protein
B	I-protein
.	O

Activation	O
of	O
T	B-cell_type
lymphocytes	I-cell_type
induces	O
an	O
NF-kappa	B-protein
B	I-protein
-like	O
binding	O
activity	O
to	O
the	O
B2	B-DNA
site	O
,	O
concomitant	O
with	O
activation	O
of	O
the	O
proenkephalin	B-DNA
promoter	I-DNA
.	O

Mutations	O
at	O
the	O
B2	B-DNA
site	O
abolish	O
this	O
transcriptional	O
activation	O
.	O

The	O
purified	O
homodimer	B-protein
(	O
two	O
p50s	B-protein
)	O
of	O
the	O
DNA-binding	B-protein
subunit	I-protein
of	O
NF-kappa	B-protein
B	I-protein
binds	O
the	O
B2	B-DNA
site	O
of	O
proenkephalin	O
relatively	O
better	O
than	O
does	O
the	O
heterotetramer	B-protein
(	O
two	O
p65s	B-protein
plus	O
two	O
p50s	B-protein
)	O
form	O
of	O
the	O
factor	O
.	O

Thus	O
,	O
it	O
appears	O
that	O
the	O
T-cell-specific	O
activation	O
of	O
the	O
proenkephalin	B-DNA
promoter	I-DNA
is	O
mediated	O
by	O
NF-kappa	B-protein
B	I-protein
.	O

However	O
,	O
as	O
NF-kappa	B-protein
B	I-protein
is	O
ubiquitous	O
and	O
the	O
transcriptional	O
activation	O
through	O
the	O
B2	B-DNA
site	O
is	O
T	O
cell	O
specific	O
,	O
yet	O
another	O
T-cell-specific	B-protein
factor	I-protein
which	O
synergizes	O
with	O
NF-kappa	B-protein
B	I-protein
should	O
be	O
considered	O
.	O

MoLECULAR	NULL
AND	NULL
CELLULAR	NULL
BIOLOGY	NULL
,	NULL
Feb.	NULL
1991	NULL
,	NULL
p.	NULL
1017-1022	NULL
0270-7306/91/021017-06	NULL
$	NULL
02.00/0	NULL
Copyright	NULL
©	NULL
1991	NULL
,	NULL
American	NULL
Society	NULL
for	NULL
Microbiology	NULL
Vol	NULL
.	NULL

11	NULL
,	NULL
No	NULL
.	NULL

2	NULL
Nuclear	NULL
Factor	NULL
kB	NULL
Activates	NULL
Proenkephalin	NULL
Transcription	NULL
in	NULL
T	NULL
Lymphocytes	NULL
AMIR	NULL
RATTNER	NULL
,	NULL
'	NULL
MIRA	NULL
KORNER	NULL
,	NULL
'	NULL
HAIM	NULL
ROSEN	NULL
,	NULL
``	NULL
PATRICK	NULL
A.	NULL
BAEUERLE	NULL
,	NULL
``	NULL
anp	NULL
YOAV	NULL
CITRLI'*	NULL
Department	NULL
of	NULL
Hormone	NULL
Research	NULL
,	NULL
The	NULL
Weizmann	NULL
Institute	NULL
of	NULL
Science	NULL
,	NULL
Rehovot	NULL
,	NULL
76100	NULL
,	NULL
and	NULL
Department	NULL
of	NULL
Molecular	NULL
Virology	NULL
,	NULL
The	NULL
Hebrew	NULL
University	NULL
of	NULL
Jerusalem	NULL
Medical	NULL
School	NULL
,	NULL
Jerusalem	NULL
,	NULL
``	NULL
Israel	NULL
,	NULL
and	NULL
Gene	NULL
Center	NULL
,	NULL
Ludwig-Maximilians-University	NULL
Munich	NULL
,	NULL
Am	NULL
Klopferspitz	NULL
,	NULL
D-8033	NULL
Martinsried	NULL
,	NULL
Federal	NULL
Republic	NULL
of	NULL
Germany	NULL
Received	NULL
1	NULL
August	NULL
1990/Accepted	NULL
14	NULL
October	NULL
1990	NULL
Upon	NULL
activation	NULL
,	NULL
T	NULL
lymphocytes	NULL
accumulate	NULL
high	NULL
levels	NULL
of	NULL
the	NULL
neuropeptide	NULL
enkephalin	NULL
which	NULL
correlate	NULL
with	NULL
high	NULL
levels	NULL
of	NULL
proenkephalin	NULL
mRNA	NULL
in	NULL
the	NULL
cells	NULL
.	NULL

Here	NULL
we	NULL
investigated	NULL
the	NULL
transcriptional	NULL
basis	NULL
for	NULL
these	NULL
changes	NULL
.	NULL

The	NULL
proenkephalin	NULL
promoter	NULL
contains	NULL
a	NULL
sequence	NULL
GGGGACGTCCCC	NULL
,	NULL
named	NULL
B2	NULL
,	NULL
which	NULL
is	NULL
similar	NULL
to	NULL
the	NULL
«	NULL
B	NULL
sequence	NULL
GGGGACTTTCC	NULL
,	NULL
the	NULL
binding	NULL
site	NULL
of	NULL
the	NULL
transcription	NULL
factor	NULL
nuclear	NULL
factor	NULL
(	NULL
NF	NULL
)	NULL
-	NULL
<	NULL
B	NULL
.	NULL

Activation	NULL
of	NULL
T	NULL
lymphocytes	NULL
induces	NULL
an	NULL
NF-	NULL
«	NULL
B-like	NULL
binding	NULL
activity	NULL
to	NULL
the	NULL
B2	NULL
site	NULL
,	NULL
concomitant	NULL
with	NULL
activation	NULL
of	NULL
the	NULL
proenkephalin	NULL
promoter	NULL
.	NULL

Mutations	NULL
at	NULL
the	NULL
B2	NULL
site	NULL
abolish	NULL
this	NULL
transcriptional	NULL
activation	NULL
.	NULL

The	NULL
purified	NULL
homodimer	NULL
(	NULL
two	NULL
pS50s	NULL
)	NULL
of	NULL
the	NULL
DNA-binding	NULL
subunit	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
binds	NULL
the	NULL
B2	NULL
site	NULL
of	NULL
proenkephalin	NULL
relatively	NULL
better	NULL
than	NULL
does	NULL
the	NULL
heterotetramer	NULL
(	NULL
two	NULL
p6GSs	NULL
plus	NULL
two	NULL
p50s	NULL
)	NULL
form	NULL
of	NULL
the	NULL
factor	NULL
.	NULL

Thus	NULL
,	NULL
it	NULL
appears	NULL
that	NULL
the	NULL
T-cell-specific	NULL
activation	NULL
of	NULL
the	NULL
proenkephalin	NULL
promoter	NULL
is	NULL
mediated	NULL
by	NULL
NF-	NULL
«	NULL
B	NULL
.	NULL

However	NULL
,	NULL
as	NULL
NF-	NULL
«	NULL
B	NULL
is	NULL
ubiquitous	NULL
and	NULL
the	NULL
transcriptional	NULL
activation	NULL
through	NULL
the	NULL
B2	NULL
site	NULL
is	NULL
T	NULL
cell	NULL
specific	NULL
,	NULL
yet	NULL
another	NULL
T-cell-specific	NULL
factor	NULL
which	NULL
synergizes	NULL
with	NULL
NF-xB	NULL
should	NULL
be	NULL
considered	NULL
.	NULL

Proenkephalin	NULL
is	NULL
a	NULL
precursor	NULL
for	NULL
neuropeptides	NULL
with	NULL
a	NULL
variety	NULL
of	NULL
functions	NULL
in	NULL
the	NULL
neuroendocrine	NULL
and	NULL
nervous	NULL
systems	NULL
(	NULL
1	NULL
)	NULL
.	NULL

Upon	NULL
activation	NULL
,	NULL
T-helper	NULL
lymphocytes	NULL
were	NULL
found	NULL
to	NULL
express	NULL
high	NULL
levels	NULL
of	NULL
proenkephalin	NULL
mRNA	NULL
and	NULL
to	NULL
secrete	NULL
large	NULL
amounts	NULL
of	NULL
the	NULL
metenkephalin	NULL
neuropeptide	NULL
,	NULL
perhaps	NULL
indicating	NULL
an	NULL
axis	NULL
by	NULL
which	NULL
the	NULL
immune	NULL
and	NULL
nervous	NULL
systems	NULL
interact	NULL
(	NULL
33	NULL
)	NULL
.	NULL

Nuclear	NULL
factor	NULL
(	NULL
NF	NULL
)	NULL
-	NULL
«	NULL
B	NULL
is	NULL
a	NULL
transcription	NULL
factor	NULL
originally	NULL
found	NULL
to	NULL
be	NULL
expressed	NULL
in	NULL
mature	NULL
B	NULL
lymphocytes	NULL
,	NULL
in	NULL
which	NULL
it	NULL
enhances	NULL
the	NULL
expression	NULL
of	NULL
the	NULL
immunoglobulin	NULL
x	NULL
light-chain	NULL
gene	NULL
(	NULL
28	NULL
)	NULL
.	NULL

Subsequently	NULL
,	NULL
NF-kB	NULL
was	NULL
found	NULL
to	NULL
be	NULL
present	NULL
in	NULL
an	NULL
inactive	NULL
form	NULL
in	NULL
many	NULL
cell	NULL
types	NULL
in	NULL
which	NULL
,	NULL
upon	NULL
a	NULL
posttranslational	NULL
activation	NULL
step	NULL
mediated	NULL
by	NULL
protein	NULL
kinase	NULL
C	NULL
(	NULL
8	NULL
,	NULL
19	NULL
,	NULL
21	NULL
,	NULL
22	NULL
,	NULL
24	NULL
,	NULL
29	NULL
)	NULL
or	NULL
various	NULL
other	NULL
treatments	NULL
(	NULL
17	NULL
,	NULL
23	NULL
,	NULL
30	NULL
)	NULL
,	NULL
it	NULL
becomes	NULL
active	NULL
.	NULL

The	NULL
biochemical	NULL
basis	NULL
for	NULL
the	NULL
activation	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
was	NULL
shown	NULL
to	NULL
involve	NULL
dissociation	NULL
of	NULL
an	NULL
inhibitory	NULL
subunit	NULL
,	NULL
termed	NULL
IkB	NULL
,	NULL
from	NULL
the	NULL
DNA-binding	NULL
sub-unit	NULL
(	NULL
s	NULL
)	NULL
(	NULL
3	NULL
,	NULL
4	NULL
)	NULL
.	NULL

Mitogenic	NULL
stimulation	NULL
of	NULL
T	NULL
lymphocytes	NULL
also	NULL
converts	NULL
inactive	NULL
NF-	NULL
«	NULL
B	NULL
into	NULL
its	NULL
active	NULL
form	NULL
,	NULL
which	NULL
in	NULL
turn	NULL
induces	NULL
the	NULL
expression	NULL
of	NULL
kB	NULL
sequence-containing	NULL
genes	NULL
such	NULL
as	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
(	NULL
21	NULL
)	NULL
,	NULL
interleukin-2	NULL
(	NULL
IL-2	NULL
)	NULL
(	NULL
14	NULL
)	NULL
,	NULL
and	NULL
the	NULL
a	NULL
subunit	NULL
of	NULL
the	NULL
IL-2	NULL
receptor	NULL
(	NULL
7	NULL
)	NULL
.	NULL

The	NULL
rat	NULL
proenkephalin	NULL
promoter	NULL
region	NULL
contains	NULL
two	NULL
sequences	NULL
(	NULL
Bl	NULL
and	NULL
B2	NULL
,	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

2a	NULL
)	NULL
that	NULL
are	NULL
similar	NULL
to	NULL
kB	NULL
,	NULL
the	NULL
binding	NULL
site	NULL
of	NULL
NF-kB	NULL
.	NULL

In	NULL
this	NULL
study	NULL
,	NULL
we	NULL
show	NULL
that	NULL
NF-	NULL
«	NULL
B	NULL
can	NULL
bind	NULL
to	NULL
the	NULL
proenkephalin	NULL
promoter	NULL
(	NULL
at	NULL
the	NULL
B2	NULL
site	NULL
)	NULL
and	NULL
that	NULL
this	NULL
binding	NULL
is	NULL
the	NULL
cause	NULL
for	NULL
the	NULL
expression	NULL
of	NULL
proenkephalin	NULL
in	NULL
activated	NULL
T	NULL
lymphocytes	NULL
.	NULL

MATERIALS	NULL
AND	NULL
METHODS	NULL
Protein	NULL
extracts	NULL
and	NULL
EMSA	NULL
.	NULL

Whole-cell	NULL
protein	NULL
extracts	NULL
were	NULL
prepared	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
16	NULL
)	NULL
.	NULL

Briefly	NULL
,	NULL
10-ml	NULL
(	NULL
2	NULL
x	NULL
10°	NULL
to	NULL
4	NULL
x	NULL
10°	NULL
cells	NULL
per	NULL
ml	NULL
)	NULL
cultures	NULL
were	NULL
washed	NULL
once	NULL
with	NULL
phosphate-buffered	NULL
saline	NULL
and	NULL
resuspended	NULL
in	NULL
0.5	NULL
ml	NULL
of	NULL
20	NULL
mM	NULL
HEPES	NULL
(	NULL
N-2-hydroxypiperazine-N'-2-ethanesulfo-nic	NULL
acid	NULL
)	NULL
(	NULL
pH	NULL
7.9	NULL
)	NULL
-0.35	NULL
M	NULL
NaCIl-20	NULL
%	NULL
glycerol-1	NULL
mM	NULL
*	NULL
Corresponding	NULL
author	NULL
.	NULL

1017	NULL
MgCl	NULL
,	NULL
-1	NULL
%	NULL
Nonidet	NULL
P-40-1	NULL
mM	NULL
dithiothreitol-0.5	NULL
mM	NULL
EDTA-0.1	NULL
mM	NULL
EGTA	NULL
containing	NULL
the	NULL
following	NULL
protease	NULL
inhibitors	NULL
:	NULL
1	NULL
mM	NULL
phenylmethylsulfonyl	NULL
fluoride	NULL
,	NULL
1	NULL
ug	NULL
of	NULL
pepstatin	NULL
A	NULL
per	NULL
ml	NULL
,	NULL
10	NULL
pg	NULL
of	NULL
leupeptin	NULL
per	NULL
ml	NULL
,	NULL
0.1	NULL
mM	NULL
p-aminobenzamidine	NULL
,	NULL
and	NULL
1	NULL
mg	NULL
of	NULL
aprotinin	NULL
per	NULL
ml	NULL
.	NULL

After	NULL
10	NULL
min	NULL
of	NULL
incubation	NULL
on	NULL
ice	NULL
,	NULL
the	NULL
extract	NULL
was	NULL
centrifuged	NULL
in	NULL
an	NULL
Eppendorf	NULL
minicentrifuge	NULL
for	NULL
15	NULL
min	NULL
at	NULL
4°C	NULL
and	NULL
the	NULL
super-natant	NULL
was	NULL
collected	NULL
,	NULL
frozen	NULL
in	NULL
liquid	NULL
N	NULL
;	NULL
,	NULL
and	NULL
kept	NULL
at	NULL
-130°C	NULL
until	NULL
thawed	NULL
for	NULL
the	NULL
electrophoretic	NULL
mobility	NULL
shift	NULL
assay	NULL
(	NULL
EMSA	NULL
)	NULL
.	NULL

For	NULL
the	NULL
EMSA	NULL
,	NULL
6	NULL
wl	NULL
of	NULL
protein	NULL
extract	NULL
(	NULL
~20	NULL
ug	NULL
of	NULL
protein	NULL
)	NULL
was	NULL
incubated	NULL
for	NULL
20	NULL
to	NULL
30	NULL
min	NULL
at	NULL
room	NULL
temperature	NULL
in	NULL
30	NULL
pl	NULL
of	NULL
10	NULL
mM	NULL
Tris	NULL
(	NULL
pH	NULL
7.5	NULL
)	NULL
-20	NULL
mM	NULL
KCl-1	NULL
mM	NULL
EDTA-1	NULL
mM	NULL
B-mercaptoethanol-4	NULL
%	NULL
glycerol-4	NULL
mg	NULL
of	NULL
poly	NULL
(	NULL
dI-dC	NULL
)	NULL
-20,000	NULL
to	NULL
50,000	NULL
Cerenkov	NULL
counts	NULL
per	NULL
minute	NULL
(	NULL
0.5	NULL
ng	NULL
)	NULL
of	NULL
radioactively	NULL
labeled	NULL
DNA	NULL
probe	NULL
.	NULL

An	NULL
equal	NULL
volume	NULL
of	NULL
loading	NULL
buffer	NULL
(	NULL
16	NULL
)	NULL
was	NULL
added	NULL
to	NULL
the	NULL
binding	NULL
reaction	NULL
mixture	NULL
before	NULL
electrophoresis	NULL
through	NULL
a	NULL
4	NULL
%	NULL
native	NULL
polyacrylamide	NULL
gel	NULL
(	NULL
16	NULL
)	NULL
.	NULL

Purification	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
and	NULL
its	NULL
assay	NULL
by	NULL
EMSA	NULL
was	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
31	NULL
,	NULL
32	NULL
)	NULL
.	NULL

Plasmids	NULL
and	NULL
DNA	NULL
fragments	NULL
.	NULL

The	NULL
following	NULL
DNA	NULL
fragments	NULL
were	NULL
used	NULL
:	NULL
«	NULL
kB	NULL
,	NULL
the	NULL
Xbal-EcoRI	NULL
fragment	NULL
containing	NULL
the	NULL
kB	NULL
oligonucleotide	NULL
subcloned	NULL
into	NULL
the	NULL
BamHI	NULL
site	NULL
of	NULL
pUC18	NULL
(	NULL
16	NULL
)	NULL
;	NULL
B1	NULL
and	NULL
mB1	NULL
,	NULL
the	NULL
XmnlI-Aval	NULL
fragments	NULL
containing	NULL
the	NULL
relevant	NULL
sequences	NULL
of	NULL
pEPCAT	NULL
(	NULL
wt	NULL
)	NULL
and	NULL
pEPCAT	NULL
(	NULL
mB1B2	NULL
)	NULL
,	NULL
respectively	NULL
(	NULL
see	NULL
Fig	NULL
.	NULL

2a	NULL
)	NULL
;	NULL
B2	NULL
and	NULL
mB2	NULL
,	NULL
the	NULL
Aval-Pstl	NULL
fragments	NULL
containing	NULL
the	NULL
relevant	NULL
sequences	NULL
of	NULL
the	NULL
same	NULL
plasmids	NULL
;	NULL
x-2	NULL
,	NULL
a	NULL
fragment	NULL
of	NULL
the	NULL
x	NULL
light-chain	NULL
gene	NULL
enhancer	NULL
,	NULL
which	NULL
was	NULL
prepared	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
28	NULL
)	NULL
.	NULL

In	NULL
the	NULL
experiments	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

3	NULL
,	NULL
the	NULL
B2	NULL
fragment	NULL
was	NULL
the	NULL
oligonucleotide	NULL
AGGGGACGTCCCCTTAGCA	NULL
cloned	NULL
into	NULL
the	NULL
PstI	NULL
site	NULL
of	NULL
pGEM-2	NULL
.	NULL

For	NULL
construction	NULL
of	NULL
the	NULL
proenkephalin	NULL
promoter-cat	NULL
gene	NULL
reporter	NULL
plasmid	NULL
,	NULL
the	NULL
Xbal-Sacl	NULL
fragment	NULL
spanning	NULL
nucleo-tides	NULL
-501	NULL
to	NULL
+51	NULL
relative	NULL
to	NULL
the	NULL
rat	NULL
proenkephalin	NULL
gene	NULL
cap	NULL
site	NULL
(	NULL
26	NULL
)	NULL
was	NULL
subcloned	NULL
into	NULL
pGEM-2	NULL
.	NULL

Mutations	NULL
were	NULL
introduced	NULL
by	NULL
the	NULL
oligonucleotide-directed	NULL
gap	NULL
heteroduplex	NULL
technique	NULL
(	NULL
20	NULL
)	NULL
.	NULL

The	NULL
bacterial	NULL
cat	NULL
gene	NULL
was	NULL
subsequently	NULL
inserted	NULL
at	NULL
the	NULL
Sacl	NULL
site	NULL
downstream	NULL
of	NULL
the	NULL
cap	NULL
site	NULL
of	NULL
either	NULL
1018	NULL
RATTNER	NULL
ET	NULL
AL	NULL
.	NULL

Mor	NULL
.	NULL

CELL	NULL
.	NULL

BioL	NULL
.	NULL

a	NULL
KB	NULL
B2	NULL
mB2	NULL
k-2	NULL
pProbe	NULL
_	NULL
:	NULL
B	NULL
Bi	NULL
B1	NULL
B2	NULL
Con	NULL
A	NULL
+PMA	NULL
:	NULL
[	NULL
+	NULL
+	NULL
+	NULL
-y	NULL
-	NULL
Competitor	NULL
-	NULL
'-	NULL
+/	NULL
.-Competitor	NULL
:	NULL
-	NULL
-	NULL
-	NULL
+	NULL
-	NULL
-	NULL
$	NULL
-_-	NULL
-	NULL
|	NULL
%	NULL
vc-	NULL
<	NULL
o-	NULL
C	NULL
#	NULL
&	NULL
NF-KB	NULL
-	NULL
{	NULL
'	NULL
f	NULL
.	NULL

e	NULL
12-3	NULL
4	NULL
C.	NULL
2	NULL
-	NULL
-3	NULL
FIG	NULL
.	NULL

1	NULL
.	NULL

B2	NULL
site	NULL
of	NULL
the	NULL
proenkephalin	NULL
promoter	NULL
is	NULL
recognized	NULL
by	NULL
an	NULL
NF-	NULL
«	NULL
xB-like	NULL
protein	NULL
.	NULL

(	NULL
a	NULL
)	NULL
Whole-cell	NULL
extracts	NULL
from	NULL
ConA-PMA-activated	NULL
(	NULL
lanes	NULL
1	NULL
,	NULL
3	NULL
,	NULL
4	NULL
,	NULL
6	NULL
,	NULL
7	NULL
,	NULL
and	NULL
9	NULL
)	NULL
and	NULL
nontreated	NULL
control	NULL
(	NULL
lanes	NULL
2	NULL
,	NULL
5	NULL
,	NULL
8	NULL
,	NULL
and	NULL
10	NULL
)	NULL
Jurkat	NULL
T	NULL
cells	NULL
were	NULL
reacted	NULL
with	NULL
labeled	NULL
DNA	NULL
fragments	NULL
containing	NULL
the	NULL
kB	NULL
sequence	NULL
(	NULL
lanes	NULL
1	NULL
and	NULL
2	NULL
)	NULL
,	NULL
the	NULL
proenkephalin	NULL
B2	NULL
site	NULL
(	NULL
lanes	NULL
3	NULL
to	NULL
5	NULL
)	NULL
,	NULL
the	NULL
mutated	NULL
B2	NULL
site	NULL
(	NULL
mB2	NULL
)	NULL
(	NULL
lanes	NULL
6	NULL
to	NULL
8	NULL
)	NULL
,	NULL
and	NULL
the	NULL
x-2	NULL
fragment	NULL
(	NULL
lanes	NULL
9	NULL
and	NULL
10	NULL
)	NULL
,	NULL
which	NULL
contains	NULL
the	NULL
recognition	NULL
site	NULL
of	NULL
the	NULL
ubiquitous	NULL
factor	NULL
NF-uE3	NULL
and	NULL
was	NULL
used	NULL
to	NULL
control	NULL
for	NULL
the	NULL
amount	NULL
of	NULL
protein	NULL
in	NULL
the	NULL
two	NULL
types	NULL
of	NULL
extracts	NULL
.	NULL

Lanes	NULL
4	NULL
and	NULL
7	NULL
present	NULL
reactions	NULL
in	NULL
which	NULL
an	NULL
excess	NULL
(	NULL
50	NULL
ng	NULL
)	NULL
of	NULL
unlabeled	NULL
kB	NULL
fragment	NULL
(	NULL
see	NULL
below	NULL
)	NULL
was	NULL
included	NULL
in	NULL
the	NULL
reaction	NULL
.	NULL

Jurkat	NULL
cells	NULL
were	NULL
treated	NULL
for	NULL
24	NULL
h	NULL
with	NULL
PMA	NULL
(	NULL
100	NULL
nM	NULL
,	NULL
Sigma	NULL
)	NULL
and	NULL
ConA	NULL
(	NULL
Sigma	NULL
type	NULL
IV	NULL
,	NULL
50	NULL
ug/ml1	NULL
)	NULL
,	NULL
after	NULL
which	NULL
protein	NULL
extracts	NULL
were	NULL
prepared	NULL
from	NULL
them	NULL
as	NULL
described	NULL
in	NULL
Materials	NULL
and	NULL
Methods	NULL
.	NULL

(	NULL
b	NULL
)	NULL
EMSA	NULL
with	NULL
a	NULL
whole-cell	NULL
extract	NULL
from	NULL
$	NULL
194	NULL
plasmacytoma	NULL
cells	NULL
.	NULL

The	NULL
extract	NULL
was	NULL
reacted	NULL
with	NULL
the	NULL
kB	NULL
probe	NULL
(	NULL
lane	NULL
1	NULL
)	NULL
,	NULL
the	NULL
B1	NULL
probe	NULL
without	NULL
(	NULL
lane	NULL
2	NULL
)	NULL
or	NULL
with	NULL
(	NULL
lane	NULL
3	NULL
)	NULL
an	NULL
excess	NULL
(	NULL
50	NULL
ng	NULL
)	NULL
of	NULL
unlabeled	NULL
«	NULL
B	NULL
fragment	NULL
,	NULL
and	NULL
the	NULL
B2	NULL
probe	NULL
(	NULL
lane	NULL
4	NULL
)	NULL
(	NULL
see	NULL
Materials	NULL
and	NULL
Methods	NULL
)	NULL
.	NULL

The	NULL
lower	NULL
basal	NULL
levels	NULL
of	NULL
NF-xB*	NULL
(	NULL
see	NULL
text	NULL
)	NULL
in	NULL
lane	NULL
2	NULL
(	NULL
panel	NULL
a	NULL
)	NULL
compared	NULL
with	NULL
those	NULL
in	NULL
lane	NULL
5	NULL
could	NULL
be	NULL
due	NULL
to	NULL
lower	NULL
specific	NULL
activity	NULL
of	NULL
the	NULL
xB	NULL
probe	NULL
in	NULL
this	NULL
experiment	NULL
compared	NULL
with	NULL
that	NULL
of	NULL
the	NULL
B2	NULL
probe	NULL
.	NULL

It	NULL
also	NULL
reflects	NULL
the	NULL
fact	NULL
that	NULL
the	NULL
affinity	NULL
of	NULL
NF-	NULL
«	NULL
B*	NULL
for	NULL
the	NULL
B2	NULL
site	NULL
is	NULL
somewhat	NULL
higher	NULL
than	NULL
that	NULL
for	NULL
the	NULL
xB	NULL
site	NULL
(	NULL
see	NULL
,	NULL
for	NULL
example	NULL
,	NULL
Fig	NULL
.	NULL

3a	NULL
)	NULL
.	NULL

4	NULL
5	NULL
6	NULL
-7	NULL
8	NULL
.	NULL

9	NULL
10	NULL
the	NULL
wild-type	NULL
or	NULL
the	NULL
mutated	NULL
proenkephalin	NULL
promoter	NULL
(	NULL
see	NULL
Fig	NULL
.	NULL

2a	NULL
)	NULL
.	NULL

Transfections	NULL
.	NULL

Jurkat	NULL
cells	NULL
were	NULL
transiently	NULL
transfected	NULL
by	NULL
the	NULL
DEAE-dextran	NULL
protocol	NULL
(	NULL
13	NULL
)	NULL
.	NULL

Twenty	NULL
hours	NULL
after	NULL
trans-fection	NULL
,	NULL
each	NULL
culture	NULL
was	NULL
split	NULL
into	NULL
two	NULL
,	NULL
and	NULL
one	NULL
aliquot	NULL
was	NULL
treated	NULL
with	NULL
concanavalin	NULL
A	NULL
(	NULL
ConA	NULL
)	NULL
plus	NULL
phorbol	NULL
myristate	NULL
acetate	NULL
(	NULL
PMA	NULL
)	NULL
(	NULL
50	NULL
pg/ml	NULL
and	NULL
100	NULL
nM	NULL
,	NULL
respectively	NULL
)	NULL
.	NULL

Twenty	NULL
hours	NULL
later	NULL
,	NULL
the	NULL
cells	NULL
were	NULL
harvested	NULL
and	NULL
assayed	NULL
for	NULL
chloramphenicol	NULL
acetyltransferase	NULL
activity	NULL
(	NULL
12	NULL
)	NULL
.	NULL

Incubation	NULL
was	NULL
for	NULL
4	NULL
h	NULL
at	NULL
37°C	NULL
followed	NULL
by	NULL
a	NULL
3-	NULL
to	NULL
16h	NULL
exposure	NULL
of	NULL
the	NULL
thin-layer	NULL
chromatography	NULL
plate	NULL
to	NULL
X-ray	NULL
film	NULL
.	NULL

RESULTS	NULL
NF-	NULL
«	NULL
B-like	NULL
protein	NULL
binds	NULL
B2	NULL
site	NULL
of	NULL
proenkephalin	NULL
promoter	NULL
.	NULL

The	NULL
T-cell	NULL
line	NULL
Jurkat	NULL
was	NULL
activated	NULL
by	NULL
a	NULL
combination	NULL
of	NULL
PMA	NULL
and	NULL
the	NULL
lectin	NULL
ConA	NULL
.	NULL

Such	NULL
treatments	NULL
were	NULL
reported	NULL
(	NULL
7	NULL
,	NULL
14	NULL
,	NULL
21	NULL
)	NULL
and	NULL
were	NULL
also	NULL
shown	NULL
here	NULL
to	NULL
activate	NULL
NF-	NULL
«	NULL
B	NULL
DNA-binding	NULL
activity	NULL
as	NULL
reflected	NULL
by	NULL
binding	NULL
to	NULL
the	NULL
«	NULL
B	NULL
sequence	NULL
in	NULL
the	NULL
EMSA	NULL
(	NULL
9	NULL
,	NULL
10	NULL
)	NULL
(	NULL
Fig	NULL
.	NULL

1a	NULL
,	NULL
compare	NULL
lanes	NULL
1	NULL
and	NULL
2	NULL
)	NULL
.	NULL

The	NULL
level	NULL
of	NULL
expression	NULL
of	NULL
a	NULL
constitutive	NULL
transcription	NULL
factor	NULL
,	NULL
NF-uE3	NULL
,	NULL
was	NULL
not	NULL
affected	NULL
by	NULL
the	NULL
ConA	NULL
plus	NULL
PMA	NULL
treatments	NULL
(	NULL
Fig	NULL
.	NULL

la	NULL
,	NULL
lanes	NULL
9	NULL
and	NULL
10	NULL
)	NULL
.	NULL

The	NULL
proenkephalin	NULL
promoter	NULL
contains	NULL
two	NULL
sites	NULL
which	NULL
are	NULL
similar	NULL
but	NULL
not	NULL
identical	NULL
to	NULL
the	NULL
kB	NULL
sequence	NULL
(	NULL
16	NULL
)	NULL
(	NULL
B1	NULL
and	NULL
B2	NULL
,	NULL
Fig	NULL
.	NULL

2a	NULL
)	NULL
.	NULL

We	NULL
tested	NULL
whether	NULL
NF-	NULL
«	NULL
B	NULL
can	NULL
recognize	NULL
these	NULL
sites	NULL
of	NULL
the	NULL
proenkephalin	NULL
promoter	NULL
.	NULL

An	NULL
extract	NULL
of	NULL
the	NULL
Jurkat	NULL
T-cell	NULL
line	NULL
was	NULL
reacted	NULL
in	NULL
an	NULL
EMSA	NULL
with	NULL
the	NULL
B1	NULL
or	NULL
the	NULL
B2	NULL
sequence	NULL
of	NULL
the	NULL
rat	NULL
proenkephalin	NULL
promoter	NULL
.	NULL

A	NULL
ConA-PMA-inducible	NULL
NF-	NULL
«	NULL
B-like	NULL
activity	NULL
was	NULL
shown	NULL
to	NULL
bind	NULL
specifically	NULL
to	NULL
the	NULL
B2	NULL
site	NULL
(	NULL
Fig	NULL
.	NULL

la	NULL
,	NULL
lanes	NULL
3	NULL
to	NULL
5	NULL
)	NULL
but	NULL
not	NULL
to	NULL
the	NULL
B1	NULL
site	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

An	NULL
extract	NULL
of	NULL
the	NULL
plasmacytoma	NULL
$	NULL
194	NULL
,	NULL
which	NULL
expresses	NULL
high	NULL
constitutive	NULL
levels	NULL
of	NULL
NF-KB	NULL
(	NULL
2	NULL
)	NULL
,	NULL
was	NULL
also	NULL
reacted	NULL
with	NULL
the	NULL
B1	NULL
and	NULL
B2	NULL
sequences	NULL
and	NULL
shown	NULL
to	NULL
bind	NULL
only	NULL
to	NULL
the	NULL
latter	NULL
(	NULL
Fig	NULL
.	NULL

1b	NULL
)	NULL
.	NULL

The	NULL
B2	NULL
site	NULL
is	NULL
important	NULL
for	NULL
proenkephalin	NULL
transcription	NULL
in	NULL
activated	NULL
T	NULL
cells	NULL
.	NULL

The	NULL
observations	NULL
that	NULL
an	NULL
NF-	NULL
«	NULL
B-like	NULL
activity	NULL
recognizes	NULL
the	NULL
B2	NULL
site	NULL
at	NULL
the	NULL
proenkephalin	NULL
promoter	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
)	NULL
and	NULL
that	NULL
similar	NULL
activation	NULL
treatments	NULL
of	NULL
helper	NULL
T	NULL
cells	NULL
induce	NULL
NF-	NULL
«	NULL
B	NULL
DNA-binding	NULL
activity	NULL
(	NULL
Fig	NULL
.	NULL

la	NULL
)	NULL
and	NULL
elevate	NULL
the	NULL
level	NULL
of	NULL
proenkephalin	NULL
mRNA	NULL
(	NULL
33	NULL
)	NULL
raised	NULL
the	NULL
possibility	NULL
that	NULL
activation	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
is	NULL
the	NULL
cause	NULL
for	NULL
the	NULL
expression	NULL
of	NULL
proenkephalin	NULL
in	NULL
activated	NULL
T	NULL
cells	NULL
.	NULL

To	NULL
address	NULL
this	NULL
,	NULL
we	NULL
first	NULL
constructed	NULL
a	NULL
plasmid	NULL
containing	NULL
the	NULL
rat	NULL
proenkephalin	NULL
promoter	NULL
in	NULL
front	NULL
of	NULL
a	NULL
reporter	NULL
chloramphenicol	NULL
acetyltransferase	NULL
cat	NULL
gene	NULL
[	NULL
see	NULL
pEPCAT	NULL
(	NULL
wt	NULL
)	NULL
in	NULL
Fig	NULL
.	NULL

2a	NULL
]	NULL
.	NULL

The	NULL
plasmid	NULL
was	NULL
transfected	NULL
into	NULL
Jurkat	NULL
cells	NULL
,	NULL
which	NULL
were	NULL
then	NULL
treated	NULL
with	NULL
various	NULL
concentrations	NULL
of	NULL
ConA	NULL
plus	NULL
PMA	NULL
.	NULL

Such	NULL
treatments	NULL
not	NULL
only	NULL
induced	NULL
NF-	NULL
«	NULL
B	NULL
DNA-binding	NULL
activity	NULL
(	NULL
Fig	NULL
.	NULL

la	NULL
,	NULL
lanes	NULL
1	NULL
to	NULL
5	NULL
)	NULL
but	NULL
also	NULL
produced	NULL
significant	NULL
transcriptional	NULL
activations	NULL
of	NULL
the	NULL
proenkephalin	NULL
promoter	NULL
(	NULL
Fig	NULL
.	NULL

2b	NULL
)	NULL
.	NULL

Next	NULL
,	NULL
to	NULL
determine	NULL
whether	NULL
the	NULL
observed	NULL
transcriptional	NULL
activation	NULL
is	NULL
due	NULL
to	NULL
the	NULL
action	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
,	NULL
we	NULL
mutated	NULL
the	NULL
B1	NULL
and	NULL
B2	NULL
sites	NULL
of	NULL
the	NULL
proenkephalin	NULL
promoter	NULL
.	NULL

These	NULL
mutations	NULL
(	NULL
marked	NULL
mB1	NULL
and	NULL
mB2	NULL
in	NULL
Fig	NULL
.	NULL

2a	NULL
)	NULL
abolished	NULL
binding	NULL
of	NULL
the	NULL
NF-	NULL
«	NULL
B-like	NULL
factor	NULL
to	NULL
the	NULL
B2	NULL
site	NULL
(	NULL
Fig	NULL
.	NULL

la	NULL
,	NULL
compare	NULL
lanes	NULL
3	NULL
to	NULL
5	NULL
with	NULL
lanes	NULL
6	NULL
to	NULL
8	NULL
)	NULL
.	NULL

Because	NULL
no	NULL
NF-	NULL
B-like	NULL
binding	NULL
was	NULL
observed	NULL
to	NULL
the	NULL
B1	NULL
site	NULL
,	NULL
mutating	NULL
it	NULL
did	NULL
not	NULL
affect	NULL
the	NULL
pattern	NULL
of	NULL
DNA	NULL
binding	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Vor	NULL
.	NULL

11	NULL
,	NULL
1991	NULL
NF-	NULL
«	NULL
B	NULL
ACTIVATES	NULL
PROENKEPHALIN	NULL
TRANSCRIPTION	NULL
1019	NULL
B1	NULL
_	NULL
B2	NULL
a	NULL
t	NULL
#	NULL
3	NULL
pePCAT	NULL
(	NULL
w	NULL
)	NULL
--	NULL
-O-O	NULL
.	NULL

--	NULL
--	NULL
t-t	NULL
--	NULL
|	NULL
175	NULL
|	NULL
123	NULL
26	NULL
1	NULL
CAT	NULL
Xmnl	NULL
Aval	NULL
Pstl	NULL
Sacl	NULL
GGltlsti	NULL
‘	NULL
xAGCCTCC	NULL
mB1	NULL
:	NULL
CCA	NULL
mB2	NULL
:	NULL
CACX	NULL
pEPCAT	NULL
(	NULL
mB1	NULL
)	NULL
pEPCAT	NULL
(	NULL
mB2	NULL
)	NULL
pEPCAT	NULL
(	NULL
mB1B2	NULL
)	NULL
ppMaA	NULL
:	NULL
t	NULL
+	NULL
+	NULL
-	NULL
Con	NULL
A	NULL
;	NULL
=	NULL
I0	NULL
50	NULL
I0	NULL
-	NULL
c	NULL
wt	NULL
mBIB2	NULL
mB	NULL
!	NULL

_	NULL
mB2	NULL
I	NULL
711	NULL
J	NULL
u	NULL
1	NULL
coma	NULL
tPMA	NULL
-_-	NULL
f	NULL
-_	NULL
_+	NULL
-	NULL
_+	NULL
*	NULL
@	NULL
a	NULL
&	NULL
-	NULL
e	NULL
~	NULL
¥	NULL
&	NULL
#	NULL
s	NULL
over	NULL
?	NULL

o	NULL
1	NULL
>	NULL
3	NULL
4	NULL
5	NULL
1	NULL
2	NULL
3	NULL
4	NULL
5°	NULL
6	NULL
7	NULL
B	NULL
FIG	NULL
.	NULL

2	NULL
.	NULL

Transcription	NULL
activity	NULL
of	NULL
the	NULL
proenkephalin	NULL
promoter	NULL
in	NULL
Jurkat	NULL
T	NULL
cells	NULL
.	NULL

(	NULL
a	NULL
)	NULL
Proenkephalin	NULL
promoter-cat	NULL
constructs	NULL
used	NULL
for	NULL
transfections	NULL
.	NULL

The	NULL
proenkephalin	NULL
promoter	NULL
(	NULL
27	NULL
)	NULL
is	NULL
attached	NULL
to	NULL
the	NULL
cat	NULL
gene	NULL
through	NULL
a	NULL
Sacl	NULL
site	NULL
[	NULL
pEPCAT	NULL
(	NULL
wt	NULL
)	NULL
]	NULL
.	NULL

The	NULL
B1	NULL
and	NULL
B2	NULL
binding	NULL
sites	NULL
within	NULL
the	NULL
promoter	NULL
are	NULL
indicated	NULL
.	NULL

The	NULL
mutations	NULL
introduced	NULL
into	NULL
these	NULL
sites	NULL
are	NULL
shown	NULL
below	NULL
the	NULL
wild-type	NULL
sequence	NULL
(	NULL
mB1l	NULL
and	NULL
mB2	NULL
;	NULL
x	NULL
denotes	NULL
an	NULL
A	NULL
base	NULL
in	NULL
the	NULL
B2	NULL
site	NULL
that	NULL
was	NULL
deleted	NULL
during	NULL
mutagenesis	NULL
)	NULL
.	NULL

Three	NULL
combinations	NULL
of	NULL
the	NULL
mutated	NULL
sites	NULL
were	NULL
constructed	NULL
:	NULL
pEPCAT	NULL
(	NULL
mB1	NULL
)	NULL
with	NULL
a	NULL
mutated	NULL
B1	NULL
(	NULL
mB1	NULL
)	NULL
site	NULL
and	NULL
a	NULL
wild-type	NULL
B2	NULL
site	NULL
,	NULL
pEPCAT	NULL
(	NULL
mB2	NULL
)	NULL
containing	NULL
a	NULL
wild-type	NULL
B1	NULL
site	NULL
and	NULL
a	NULL
mutated	NULL
B2	NULL
(	NULL
mB2	NULL
)	NULL
site	NULL
,	NULL
and	NULL
pEPCAT	NULL
(	NULL
mB1B2	NULL
)	NULL
,	NULL
in	NULL
which	NULL
both	NULL
sites	NULL
are	NULL
mutated	NULL
.	NULL

(	NULL
b	NULL
)	NULL
Proenkephalin	NULL
promoter-mediated	NULL
transcription	NULL
in	NULL
ConA-PMA-activated	NULL
Jurkat	NULL
T	NULL
cells	NULL
.	NULL

Jurkat	NULL
cells	NULL
were	NULL
transfected	NULL
with	NULL
pEPCAT	NULL
(	NULL
wt	NULL
)	NULL
and	NULL
24	NULL
h	NULL
later	NULL
treated	NULL
for	NULL
20	NULL
h	NULL
or	NULL
not	NULL
treated	NULL
(	NULL
lane	NULL
5	NULL
)	NULL
with	NULL
PMA	NULL
(	NULL
100	NULL
nM	NULL
)	NULL
(	NULL
lanes	NULL
1	NULL
to	NULL
3	NULL
)	NULL
and	NULL
the	NULL
indicated	NULL
concentrations	NULL
of	NULL
ConA	NULL
(	NULL
micrograms	NULL
per	NULL
milliliter	NULL
)	NULL
(	NULL
lanes	NULL
2	NULL
to	NULL
4	NULL
)	NULL
.	NULL

(	NULL
c	NULL
)	NULL
Effects	NULL
of	NULL
mutating	NULL
the	NULL
B1	NULL
and	NULL
B2	NULL
sites	NULL
on	NULL
proenkephalin	NULL
promoter	NULL
function	NULL
in	NULL
Jurkat	NULL
T	NULL
cells	NULL
.	NULL

Jurkat	NULL
cells	NULL
were	NULL
transfected	NULL
with	NULL
the	NULL
various	NULL
proenkephalin	NULL
promoter-cat	NULL
gene	NULL
constructs	NULL
indicated	NULL
in	NULL
panel	NULL
a	NULL
:	NULL
pEPCAT	NULL
(	NULL
wt	NULL
)	NULL
(	NULL
lanes	NULL
1	NULL
and	NULL
2	NULL
)	NULL
,	NULL
pEPCAT	NULL
(	NULL
mB1B2	NULL
)	NULL
(	NULL
lanes	NULL
3	NULL
and	NULL
4	NULL
)	NULL
,	NULL
pEPCAT	NULL
(	NULL
mB1	NULL
)	NULL
(	NULL
lanes	NULL
5	NULL
and	NULL
6	NULL
)	NULL
,	NULL
and	NULL
pEPCAT	NULL
(	NULL
mB2	NULL
)	NULL
(	NULL
lanes	NULL
7	NULL
and	NULL
8	NULL
)	NULL
.	NULL

Even-numbered	NULL
cultures	NULL
were	NULL
activated	NULL
with	NULL
ConA	NULL
plus	NULL
PMA	NULL
.	NULL

The	NULL
basal	NULL
activity	NULL
of	NULL
the	NULL
(	NULL
unstimulated	NULL
)	NULL
wild-type	NULL
(	NULL
wt	NULL
)	NULL
promoter	NULL
appears	NULL
lower	NULL
in	NULL
this	NULL
experiment	NULL
than	NULL
in	NULL
the	NULL
one	NULL
presented	NULL
in	NULL
panel	NULL
b	NULL
.	NULL

This	NULL
is	NULL
due	NULL
to	NULL
a	NULL
shorter	NULL
exposure	NULL
of	NULL
the	NULL
thin-layer	NULL
chromatography	NULL
plate	NULL
to	NULL
film	NULL
in	NULL
this	NULL
experiment	NULL
compared	NULL
with	NULL
the	NULL
one	NULL
in	NULL
panel	NULL
b	NULL
.	NULL

The	NULL
mutated	NULL
B1	NULL
and	NULL
B2	NULL
sequences	NULL
were	NULL
then	NULL
introduced	NULL
into	NULL
the	NULL
proenkephalin	NULL
promoter-cat	NULL
constructs	NULL
(	NULL
Fig	NULL
.	NULL

2a	NULL
)	NULL
and	NULL
transfected	NULL
into	NULL
Jurkat	NULL
cells	NULL
.	NULL

The	NULL
B1	NULL
mutation	NULL
(	NULL
mB1	NULL
)	NULL
had	NULL
no	NULL
significant	NULL
effect	NULL
on	NULL
the	NULL
ability	NULL
of	NULL
a	NULL
ConA	NULL
plus	NULL
PMA	NULL
treatment	NULL
to	NULL
activate	NULL
the	NULL
proenkephalin	NULL
promoter	NULL
in	NULL
these	NULL
T	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

2¢	NULL
,	NULL
compare	NULL
lanes	NULL
1	NULL
and	NULL
2	NULL
with	NULL
lanes	NULL
5	NULL
and	NULL
6	NULL
)	NULL
.	NULL

This	NULL
result	NULL
is	NULL
consistent	NULL
with	NULL
the	NULL
inability	NULL
of	NULL
the	NULL
NF-	NULL
«	NULL
B-like	NULL
activity	NULL
to	NULL
bind	NULL
to	NULL
the	NULL
B1	NULL
site	NULL
(	NULL
Fig	NULL
.	NULL

1b	NULL
)	NULL
.	NULL

A	NULL
construct	NULL
containing	NULL
the	NULL
two	NULL
mutated	NULL
sites	NULL
[	NULL
pEPCAT	NULL
(	NULL
mB1B2	NULL
)	NULL
]	NULL
and	NULL
one	NULL
which	NULL
consists	NULL
of	NULL
a	NULL
combination	NULL
of	NULL
the	NULL
B2	NULL
mutant	NULL
with	NULL
wild-type	NULL
B1	NULL
[	NULL
pEPCAT	NULL
(	NULL
mB2	NULL
)	NULL
]	NULL
exhibited	NULL
reduced	NULL
basal	NULL
levels	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
but	NULL
most	NULL
prominently	NULL
an	NULL
almost	NULL
complete	NULL
abolish-ment	NULL
of	NULL
the	NULL
ConA-PMA-induced	NULL
activity	NULL
of	NULL
the	NULL
proenkephalin	NULL
promoter	NULL
(	NULL
Fig	NULL
.	NULL

2¢c	NULL
,	NULL
compare	NULL
lanes	NULL
1	NULL
and	NULL
2	NULL
with	NULL
lanes	NULL
3	NULL
and	NULL
4	NULL
and	NULL
7	NULL
and	NULL
8	NULL
)	NULL
.	NULL

It	NULL
therefore	NULL
appears	NULL
that	NULL
the	NULL
native	NULL
B2	NULL
site	NULL
is	NULL
essential	NULL
for	NULL
the	NULL
inducibility	NULL
of	NULL
the	NULL
proenkephalin	NULL
promoter	NULL
by	NULL
the	NULL
T-cell	NULL
activators	NULL
ConA	NULL
and	NULL
PMA	NULL
.	NULL

Homodimeric	NULL
form	NULL
of	NULL
NF-xB	NULL
is	NULL
the	NULL
major	NULL
binder	NULL
to	NULL
the	NULL
B2	NULL
site	NULL
.	NULL

The	NULL
EMSA	NULL
size	NULL
of	NULL
the	NULL
NF-	NULL
«	NULL
B-like	NULL
complex	NULL
which	NULL
bound	NULL
the	NULL
B2	NULL
site	NULL
(	NULL
GGGGACGTCCCC	NULL
)	NULL
of	NULL
the	NULL
proenkephalin	NULL
promoter	NULL
appeared	NULL
smaller	NULL
than	NULL
the	NULL
complex	NULL
formed	NULL
with	NULL
the	NULL
canonical	NULL
«	NULL
kB	NULL
sequence	NULL
(	NULL
GGGGACTTTCC	NULL
)	NULL
.	NULL

This	NULL
was	NULL
true	NULL
both	NULL
for	NULL
extracts	NULL
from	NULL
the	NULL
ConA-PMA-induced	NULL
Jurkat	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

la	NULL
,	NULL
compare	NULL
lane	NULL
3	NULL
with	NULL
lane	NULL
1	NULL
)	NULL
and	NULL
for	NULL
those	NULL
prepared	NULL
from	NULL
the	NULL
plasmacytoma	NULL
$	NULL
194	NULL
,	NULL
expressing	NULL
constitu-tively	NULL
active	NULL
NF-	NULL
«	NULL
B	NULL
(	NULL
Fig	NULL
.	NULL

1b	NULL
,	NULL
lanes	NULL
1	NULL
and	NULL
4	NULL
)	NULL
.	NULL

To	NULL
determine	NULL
whether	NULL
these	NULL
size	NULL
differences	NULL
are	NULL
significant	NULL
,	NULL
we	NULL
first	NULL
ran	NULL
higher-resolution	NULL
EMSA	NULL
gels	NULL
.	NULL

Both	NULL
in	NULL
the	NULL
Jurkat	NULL
(	NULL
data	NULL
not	NULL
1020	NULL
RATTNER	NULL
ET	NULL
AL	NULL
.	NULL

Mor	NULL
.	NULL

CELL	NULL
.	NULL

BioL	NULL
.	NULL

a	NULL
Probe	NULL
<	NULL
B	NULL
B2	NULL
bcompetitor	NULL
:	NULL
--	NULL
xB	NULL
B2	NULL
GTP	NULL
=	NULL
3	NULL
20	NULL
=	NULL
3	NULL
20	NULL
f	NULL
“	NULL
|	NULL
|	NULL
NF-	NULL
«	NULL
B	NULL
-|	NULL
MMM	NULL
NF-	NULL
«	NULL
xB*-	NULL
|	NULL
NF-xB	NULL
--	NULL
ﬂ	NULL
Bap	NULL
NF-	NULL
<	NULL
B*	NULL
-	NULL
Sap	NULL
g	NULL
A	NULL
(	NULL
f	NULL
6	NULL
FIG	NULL
.	NULL

3	NULL
.	NULL

Smaller	NULL
form	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
(	NULL
NF-	NULL
«	NULL
B*	NULL
)	NULL
binds	NULL
the	NULL
proenkephalin	NULL
B2	NULL
and	NULL
IL-2	NULL
«	NULL
B-like	NULL
sites	NULL
.	NULL

(	NULL
a	NULL
)	NULL
Binding	NULL
of	NULL
$	NULL
194	NULL
extract	NULL
to	NULL
the	NULL
canonical	NULL
kB	NULL
site	NULL
and	NULL
to	NULL
the	NULL
B2	NULL
site	NULL
.	NULL

The	NULL
same	NULL
extract	NULL
was	NULL
reacted	NULL
in	NULL
an	NULL
EMSA	NULL
with	NULL
the	NULL
xB	NULL
probe	NULL
(	NULL
lanes	NULL
1	NULL
to	NULL
3	NULL
)	NULL
or	NULL
the	NULL
B2	NULL
probe	NULL
(	NULL
lanes	NULL
4	NULL
to	NULL
6	NULL
)	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
the	NULL
indicated	NULL
GTP	NULL
concentrations	NULL
.	NULL

In	NULL
this	NULL
experiment	NULL
,	NULL
a	NULL
6	NULL
%	NULL
Tris-glycine	NULL
gel	NULL
was	NULL
used	NULL
.	NULL

(	NULL
b	NULL
)	NULL
Binding	NULL
of	NULL
$	NULL
194	NULL
extract	NULL
to	NULL
the	NULL
IL-2	NULL
kB-like	NULL
site	NULL
.	NULL

The	NULL
extract	NULL
was	NULL
reacted	NULL
in	NULL
an	NULL
EMSA	NULL
with	NULL
an	NULL
end-labeled	NULL
DNA	NULL
fragment	NULL
containing	NULL
the	NULL
IL-2	NULL
site	NULL
(	NULL
sequence	NULL
GGGATTTCACC	NULL
;	NULL
kindly	NULL
provided	NULL
by	NULL
M.	NULL
Karin	NULL
)	NULL
.	NULL

The	NULL
binding	NULL
was	NULL
blocked	NULL
either	NULL
by	NULL
the	NULL
kB	NULL
sequence	NULL
(	NULL
20	NULL
ng	NULL
;	NULL
lane	NULL
2	NULL
)	NULL
or	NULL
by	NULL
the	NULL
B2	NULL
sequence	NULL
(	NULL
20	NULL
ng	NULL
of	NULL
the	NULL
Aval-HindIII	NULL
fragment	NULL
from	NULL
the	NULL
plasmid	NULL
described	NULL
in	NULL
Materials	NULL
and	NULL
Methods	NULL
;	NULL
lane	NULL
3	NULL
)	NULL
.	NULL

In	NULL
this	NULL
experiment	NULL
,	NULL
the	NULL
native	NULL
gel	NULL
was	NULL
5	NULL
%	NULL
in	NULL
Tris-borate	NULL
buffer	NULL
.	NULL

shown	NULL
)	NULL
and	NULL
in	NULL
the	NULL
$	NULL
194	NULL
(	NULL
Fig	NULL
.	NULL

3a	NULL
)	NULL
extracts	NULL
,	NULL
two	NULL
DNA-protein	NULL
complexes	NULL
were	NULL
observed	NULL
to	NULL
bind	NULL
to	NULL
the	NULL
kB	NULL
sequence	NULL
.	NULL

Only	NULL
the	NULL
lower	NULL
complex	NULL
,	NULL
marked	NULL
NF-	NULL
«	NULL
B*	NULL
,	NULL
showed	NULL
strong	NULL
binding	NULL
to	NULL
the	NULL
proenkephalin	NULL
B2	NULL
sequence	NULL
(	NULL
Fig	NULL
.	NULL

3a	NULL
,	NULL
lanes	NULL
4	NULL
to	NULL
6	NULL
)	NULL
.	NULL

In	NULL
agreement	NULL
with	NULL
the	NULL
GTP-activatable	NULL
nature	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
(	NULL
4	NULL
,	NULL
18	NULL
)	NULL
,	NULL
both	NULL
NF-kB	NULL
and	NULL
NF-	NULL
«	NULL
B*	NULL
were	NULL
activated	NULL
by	NULL
GTP	NULL
treatment	NULL
,	NULL
although	NULL
NF-	NULL
«	NULL
B*	NULL
appeared	NULL
to	NULL
require	NULL
higher	NULL
GTP	NULL
concentrations	NULL
(	NULL
Fig	NULL
.	NULL

3a	NULL
)	NULL
.	NULL

The	NULL
DNA-binding	NULL
activity	NULL
of	NULL
NF-kB	NULL
appears	NULL
in	NULL
two	NULL
forms	NULL
(	NULL
4	NULL
)	NULL
.	NULL

The	NULL
major	NULL
and	NULL
larger	NULL
one	NULL
is	NULL
a	NULL
heterotetramer	NULL
consisting	NULL
of	NULL
two	NULL
p65	NULL
and	NULL
two	NULL
p50	NULL
subunits	NULL
(	NULL
4	NULL
)	NULL
;	NULL
this	NULL
form	NULL
is	NULL
sensitive	NULL
to	NULL
the	NULL
action	NULL
of	NULL
the	NULL
inhibitory	NULL
subunit	NULL
IB	NULL
(	NULL
4	NULL
,	NULL
31	NULL
)	NULL
.	NULL

The	NULL
second	NULL
form	NULL
appears	NULL
to	NULL
be	NULL
a	NULL
dissociation	NULL
product	NULL
of	NULL
the	NULL
larger	NULL
complex	NULL
and	NULL
is	NULL
a	NULL
smaller	NULL
homodimeric	NULL
form	NULL
consisting	NULL
of	NULL
only	NULL
two	NULL
DNA-binding	NULL
subunits	NULL
(	NULL
two	NULL
p50	NULL
subunits	NULL
)	NULL
.	NULL

NF-	NULL
«	NULL
B*	NULL
,	NULL
which	NULL
preferentially	NULL
binds	NULL
the	NULL
B2	NULL
site	NULL
,	NULL
appeared	NULL
to	NULL
migrate	NULL
in	NULL
the	NULL
EMSA	NULL
to	NULL
the	NULL
same	NULL
position	NULL
as	NULL
does	NULL
the	NULL
homodimeric	NULL
form	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
.	NULL

We	NULL
therefore	NULL
tested	NULL
whether	NULL
NF-	NULL
«	NULL
B*	NULL
is	NULL
actually	NULL
the	NULL
homodimer	NULL
of	NULL
the	NULL
p50	NULL
subunit	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
.	NULL

Purified	NULL
preparations	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
in	NULL
either	NULL
the	NULL
heterotetrameric	NULL
or	NULL
the	NULL
homodimeric	NULL
form	NULL
were	NULL
reacted	NULL
in	NULL
the	NULL
EMSA	NULL
with	NULL
the	NULL
B2	NULL
sequence	NULL
of	NULL
the	NULL
proenkephalin	NULL
promoter	NULL
.	NULL

Both	NULL
forms	NULL
of	NULL
NF-kB	NULL
recognized	NULL
the	NULL
B2	NULL
sequence	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
)	NULL
.	NULL

However	NULL
,	NULL
when	NULL
normalized	NULL
to	NULL
the	NULL
levels	NULL
of	NULL
binding	NULL
obtained	NULL
for	NULL
each	NULL
form	NULL
with	NULL
the	NULL
canonical	NULL
xB	NULL
sequence	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
,	NULL
lanes	NULL
1	NULL
and	NULL
5	NULL
)	NULL
,	NULL
it	NULL
appeared	NULL
that	NULL
the	NULL
homodimer	NULL
binds	NULL
the	NULL
B2	NULL
site	NULL
at	NULL
least	NULL
five	NULL
times	NULL
better	NULL
than	NULL
does	NULL
the	NULL
heterotetramer	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
,	NULL
compare	NULL
the	NULL
signal	NULL
in	NULL
lanes	NULL
1	NULL
to	NULL
3	NULL
with	NULL
that	NULL
in	NULL
lanes	NULL
5	NULL
to	NULL
7	NULL
)	NULL
.	NULL

This	NULL
result	NULL
,	NULL
obtained	NULL
with	NULL
purified	NULL
proteins	NULL
,	NULL
correlates	NULL
with	NULL
the	NULL
observation	NULL
that	NULL
in	NULL
crude	NULL
extracts	NULL
(	NULL
Fig	NULL
.	NULL

3a	NULL
)	NULL
only	NULL
NF-	NULL
«	NULL
B*	NULL
exhibits	NULL
high	NULL
levels	NULL
of	NULL
binding	NULL
to	NULL
the	NULL
B2	NULL
site	NULL
.	NULL

DISCUSSION	NULL
This	NULL
study	NULL
shows	NULL
that	NULL
the	NULL
expression	NULL
of	NULL
proenkephalin	NULL
in	NULL
activated	NULL
T	NULL
cells	NULL
(	NULL
26	NULL
,	NULL
33	NULL
)	NULL
is	NULL
,	NULL
to	NULL
a	NULL
large	NULL
extent	NULL
,	NULL
the	NULL
result	NULL
of	NULL
transcriptional	NULL
activation	NULL
caused	NULL
by	NULL
interaction	NULL
of	NULL
the	NULL
transcription	NULL
factor	NULL
NF-kB	NULL
with	NULL
the	NULL
B2	NULL
site	NULL
of	NULL
the	NULL
proenkephalin	NULL
promoter	NULL
.	NULL

The	NULL
induction	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
DNA-binding	NULL
activity	NULL
by	NULL
ConA	NULL
plus	NULL
PMA	NULL
paralleled	NULL
the	NULL
activation	NULL
of	NULL
the	NULL
proenkephalin	NULL
promoter	NULL
(	NULL
Fig	NULL
.	NULL

la	NULL
,	NULL
lanes	NULL
1	NULL
to	NULL
5	NULL
,	NULL
and	NULL
Fig	NULL
.	NULL

2b	NULL
)	NULL
.	NULL

Moreover	NULL
,	NULL
point	NULL
mutations	NULL
(	NULL
Fig	NULL
.	NULL

2a	NULL
)	NULL
that	NULL
abolished	NULL
the	NULL
ability	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
to	NULL
recognize	NULL
the	NULL
B2	NULL
site	NULL
(	NULL
Fig	NULL
.	NULL

la	NULL
,	NULL
lanes	NULL
6	NULL
to	NULL
8	NULL
)	NULL
rendered	NULL
the	NULL
proenkephalin	NULL
promoter	NULL
unresponsive	NULL
to	NULL
the	NULL
T-cell	NULL
activators	NULL
ConA	NULL
and	NULL
PMA	NULL
(	NULL
Fig	NULL
.	NULL

2¢	NULL
)	NULL
.	NULL

The	NULL
B2	NULL
site	NULL
of	NULL
the	NULL
proenkephalin	NULL
promoter	NULL
can	NULL
therefore	NULL
be	NULL
considered	NULL
an	NULL
addi-tional	NULL
,	NULL
hitherto	NULL
unrecognized	NULL
(	NULL
5	NULL
,	NULL
6	NULL
)	NULL
,	NULL
regulatory	NULL
element	NULL
of	NULL
this	NULL
promoter	NULL
.	NULL

Its	NULL
present	NULL
characterization	NULL
resolves	NULL
the	NULL
transcriptional	NULL
basis	NULL
for	NULL
the	NULL
enigmatic	NULL
appearance	NULL
of	NULL
high	NULL
levels	NULL
of	NULL
enkephalin	NULL
in	NULL
activated	NULL
T	NULL
lymphocytes	NULL
(	NULL
26	NULL
,	NULL
33	NULL
)	NULL
.	NULL

The	NULL
NF-	NULL
«	NULL
B-like	NULL
activity	NULL
(	NULL
marked	NULL
also	NULL
NF-	NULL
«	NULL
xB*	NULL
)	NULL
that	NULL
binds	NULL
the	NULL
B2	NULL
sequence	NULL
appeared	NULL
to	NULL
migrate	NULL
differently	NULL
in	NULL
the	NULL
EMSA	NULL
than	NULL
did	NULL
the	NULL
complex	NULL
that	NULL
binds	NULL
the	NULL
canonical	NULL
kB	NULL
sequence	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
and	NULL
3a	NULL
)	NULL
.	NULL

The	NULL
size	NULL
difference	NULL
of	NULL
the	NULL
com	NULL
Vor	NULL
.	NULL

11	NULL
,	NULL
1991	NULL
NF-xB	NULL
:	NULL
Heterotetramer	NULL
Homodimer	NULL
probe	NULL
:	NULL
xB	NULL
xB	NULL
B2	NULL
B2	NULL
«	NULL
B	NULL
«	NULL
B	NULL
B2	NULL
B2	NULL
competitor	NULL
:	NULL
``	NULL
-	NULL
xB	NULL
~	NULL
B2	NULL
-~	NULL
«	NULL
B	NULL
~	NULL
B2	NULL
>	NULL
,	NULL
“	NULL
“	NULL
U	NULL
<	NULL
12	NULL
FIG	NULL
.	NULL

4	NULL
.	NULL

Binding	NULL
of	NULL
purified	NULL
NF-	NULL
«	NULL
B	NULL
to	NULL
the	NULL
proenkephalin	NULL
B2	NULL
site	NULL
.	NULL

NF-	NULL
«	NULL
B	NULL
preparations	NULL
which	NULL
were	NULL
purified	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
31	NULL
,	NULL
32	NULL
)	NULL
were	NULL
reacted	NULL
in	NULL
EMSA	NULL
with	NULL
either	NULL
the	NULL
«	NULL
B	NULL
(	NULL
lanes	NULL
1	NULL
,	NULL
2	NULL
,	NULL
5	NULL
,	NULL
and	NULL
6	NULL
)	NULL
-	NULL
or	NULL
the	NULL
B2	NULL
(	NULL
lanes	NULL
3	NULL
,	NULL
4	NULL
,	NULL
7	NULL
,	NULL
and	NULL
8	NULL
)	NULL
-containing	NULL
DNA	NULL
fragment	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
unlabeled	NULL
«	NULL
kB	NULL
competitor	NULL
(	NULL
lanes	NULL
2	NULL
and	NULL
6	NULL
)	NULL
or	NULL
B2	NULL
competitor	NULL
(	NULL
lanes	NULL
4	NULL
and	NULL
8	NULL
)	NULL
.	NULL

Competitors	NULL
were	NULL
as	NULL
described	NULL
in	NULL
the	NULL
legend	NULL
to	NULL
Fig	NULL
.	NULL

3b	NULL
.	NULL

In	NULL
lanes	NULL
1	NULL
to	NULL
4	NULL
,	NULL
the	NULL
larger	NULL
heterotetramer	NULL
(	NULL
two	NULL
p50	NULL
subunits	NULL
plus	NULL
two	NULL
p65	NULL
subunits	NULL
)	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
(	NULL
arrowhead	NULL
)	NULL
was	NULL
used	NULL
(	NULL
the	NULL
lower	NULL
band	NULL
is	NULL
probably	NULL
a	NULL
proteolytic	NULL
product	NULL
of	NULL
the	NULL
factor	NULL
[	NULL
4	NULL
]	NULL
)	NULL
.	NULL

In	NULL
lanes	NULL
5	NULL
to	NULL
8	NULL
,	NULL
the	NULL
smaller	NULL
homodimeric	NULL
(	NULL
two	NULL
p50	NULL
subunits	NULL
)	NULL
form	NULL
of	NULL
the	NULL
factor	NULL
was	NULL
used	NULL
.	NULL

plexes	NULL
can	NULL
be	NULL
attributed	NULL
to	NULL
the	NULL
fact	NULL
that	NULL
the	NULL
major	NULL
activity	NULL
binding	NULL
to	NULL
the	NULL
proenkephalin	NULL
B2	NULL
site	NULL
is	NULL
the	NULL
faster-migrating	NULL
homodimeric	NULL
form	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
,	NULL
whereas	NULL
the	NULL
kB	NULL
sequence	NULL
is	NULL
bound	NULL
better	NULL
by	NULL
the	NULL
slower-migrating	NULL
heterotetrameric	NULL
form	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
)	NULL
.	NULL

That	NULL
indeed	NULL
NF-	NULL
«	NULL
B*	NULL
is	NULL
the	NULL
homodimer	NULL
of	NULL
the	NULL
p50	NULL
subunit	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
is	NULL
supported	NULL
by	NULL
the	NULL
following	NULL
:	NULL
(	NULL
i	NULL
)	NULL
its	NULL
coinduction	NULL
with	NULL
NF-	NULL
«	NULL
B	NULL
(	NULL
Fig	NULL
.	NULL

la	NULL
,	NULL
lanes	NULL
1	NULL
to	NULL
5	NULL
)	NULL
;	NULL
(	NULL
ii	NULL
)	NULL
the	NULL
GTP-activatable	NULL
nature	NULL
of	NULL
its	NULL
DNA	NULL
binding	NULL
(	NULL
Fig	NULL
.	NULL

3a	NULL
)	NULL
,	NULL
characteristic	NULL
of	NULL
both	NULL
forms	NULL
of	NULL
NF-kB	NULL
(	NULL
4	NULL
,	NULL
17	NULL
)	NULL
;	NULL
and	NULL
(	NULL
iii	NULL
)	NULL
most	NULL
importantly	NULL
,	NULL
a	NULL
comparison	NULL
of	NULL
its	NULL
properties	NULL
with	NULL
those	NULL
of	NULL
the	NULL
purified	NULL
p50	NULL
homodimer	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
)	NULL
-both	NULL
proteins	NULL
had	NULL
similar	NULL
electrophoretic	NULL
mobilities	NULL
in	NULL
the	NULL
EMSA	NULL
,	NULL
i.e	NULL
.	NULL

,	NULL
slightly	NULL
faster	NULL
than	NULL
the	NULL
heterotetramic	NULL
form	NULL
of	NULL
the	NULL
factor	NULL
(	NULL
Fig	NULL
.	NULL

3a	NULL
and	NULL
4	NULL
)	NULL
,	NULL
and	NULL
both	NULL
NF-	NULL
«	NULL
B*	NULL
and	NULL
the	NULL
p50	NULL
homodimer	NULL
had	NULL
the	NULL
same	NULL
DNA-binding	NULL
preferences	NULL
.	NULL

The	NULL
two	NULL
proteins	NULL
bound	NULL
the	NULL
B2	NULL
site	NULL
of	NULL
proenkephalin	NULL
as	NULL
well	NULL
as	NULL
,	NULL
if	NULL
not	NULL
better	NULL
than	NULL
,	NULL
the	NULL
canonical	NULL
kB	NULL
sequence	NULL
(	NULL
Fig	NULL
.	NULL

3a	NULL
and	NULL
4	NULL
)	NULL
.	NULL

This	NULL
is	NULL
in	NULL
sharp	NULL
contrast	NULL
to	NULL
the	NULL
heterotetrameric	NULL
form	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
,	NULL
which	NULL
had	NULL
at	NULL
least	NULL
fivefold	NULL
higher	NULL
affinity	NULL
for	NULL
the	NULL
kB	NULL
site	NULL
(	NULL
Fig	NULL
.	NULL

3a	NULL
and	NULL
4	NULL
)	NULL
.	NULL

All	NULL
cells	NULL
that	NULL
express	NULL
significant	NULL
levels	NULL
of	NULL
NF-KB	NULL
also	NULL
express	NULL
the	NULL
p50	NULL
homodimer	NULL
of	NULL
the	NULL
factor	NULL
(	NULL
4	NULL
,	NULL
31	NULL
)	NULL
.	NULL

It	NULL
is	NULL
likely	NULL
therefore	NULL
that	NULL
NF-	NULL
«	NULL
B*	NULL
,	NULL
the	NULL
major	NULL
NF-	NULL
«	NULL
xB-like	NULL
DNA-binding	NULL
activity	NULL
to	NULL
the	NULL
B2	NULL
site	NULL
of	NULL
the	NULL
proenkephalin	NULL
promoter	NULL
,	NULL
is	NULL
the	NULL
p50	NULL
NF-	NULL
«	NULL
B	NULL
ACTIVATES	NULL
PROENKEPHALIN	NULL
TRANSCRIPTION	NULL
1021	NULL
homodimer	NULL
of	NULL
NF-kB	NULL
.	NULL

Notably	NULL
,	NULL
recent	NULL
cDNA	NULL
cloning	NULL
experiments	NULL
have	NULL
shown	NULL
the	NULL
p50	NULL
homodimer	NULL
to	NULL
probably	NULL
be	NULL
identical	NULL
to	NULL
the	NULL
transcription	NULL
factor	NULL
KBF1	NULL
(	NULL
11	NULL
,	NULL
15	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
NF-	NULL
«	NULL
B*	NULL
,	NULL
KBF1	NULL
,	NULL
and	NULL
the	NULL
p50	NULL
homodimer	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
appear	NULL
to	NULL
be	NULL
the	NULL
same	NULL
entity	NULL
,	NULL
but	NULL
whether	NULL
additional	NULL
(	NULL
mainly	NULL
posttrans-lational	NULL
)	NULL
modifications	NULL
differentiate	NULL
among	NULL
these	NULL
three	NULL
proteins	NULL
remains	NULL
to	NULL
be	NULL
seen	NULL
.	NULL

The	NULL
B2	NULL
site	NULL
,	NULL
through	NULL
which	NULL
NF-	NULL
«	NULL
B	NULL
activates	NULL
proenkephalin	NULL
transcription	NULL
in	NULL
T	NULL
lymphocytes	NULL
,	NULL
as	NULL
well	NULL
as	NULL
the	NULL
B1	NULL
site	NULL
,	NULL
which	NULL
is	NULL
not	NULL
recognized	NULL
by	NULL
NF-KB	NULL
,	NULL
are	NULL
also	NULL
binding	NULL
sites	NULL
for	NULL
BETA	NULL
,	NULL
a	NULL
brain-specific	NULL
transcription	NULL
activator	NULL
expressed	NULL
only	NULL
in	NULL
brain	NULL
cells	NULL
(	NULL
16	NULL
)	NULL
.	NULL

But	NULL
,	NULL
curiously	NULL
,	NULL
in	NULL
primary	NULL
cultures	NULL
of	NULL
cerebellar	NULL
neurons	NULL
that	NULL
express	NULL
BETA	NULL
,	NULL
the	NULL
mutations	NULL
at	NULL
the	NULL
B1	NULL
and	NULL
B2	NULL
sites	NULL
did	NULL
not	NULL
have	NULL
a	NULL
marked	NULL
effect	NULL
on	NULL
proenkephalin	NULL
promoter	NULL
function	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

This	NULL
suggests	NULL
that	NULL
although	NULL
NF-	NULL
«	NULL
B	NULL
and	NULL
BETA	NULL
can	NULL
both	NULL
bind	NULL
to	NULL
the	NULL
B2	NULL
site	NULL
,	NULL
they	NULL
differ	NULL
in	NULL
their	NULL
transcriptional	NULL
activation	NULL
capacity	NULL
with	NULL
regard	NULL
to	NULL
the	NULL
proenkephalin	NULL
promoter	NULL
.	NULL

Furthermore	NULL
,	NULL
NF-	NULL
«	NULL
B	NULL
in	NULL
both	NULL
its	NULL
forms	NULL
is	NULL
present	NULL
in	NULL
many	NULL
cell	NULL
types	NULL
other	NULL
than	NULL
T	NULL
cells	NULL
,	NULL
for	NULL
example	NULL
,	NULL
the	NULL
plasmacytoma	NULL
$	NULL
194	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
)	NULL
.	NULL

However	NULL
,	NULL
transfection	NULL
of	NULL
the	NULL
proenkephalin	NULL
promoter-cat	NULL
construct	NULL
into	NULL
$	NULL
194	NULL
cells	NULL
that	NULL
were	NULL
either	NULL
treated	NULL
or	NULL
not	NULL
with	NULL
ConA	NULL
plus	NULL
PMA	NULL
did	NULL
not	NULL
result	NULL
in	NULL
transcriptional	NULL
activation	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
the	NULL
mutation	NULL
at	NULL
the	NULL
B2	NULL
site	NULL
did	NULL
not	NULL
have	NULL
any	NULL
effect	NULL
on	NULL
the	NULL
activity	NULL
of	NULL
the	NULL
promoter	NULL
in	NULL
cells	NULL
other	NULL
than	NULL
T	NULL
lymphocytes	NULL
.	NULL

It	NULL
thus	NULL
appears	NULL
that	NULL
the	NULL
action	NULL
of	NULL
NF-kB	NULL
in	NULL
the	NULL
context	NULL
of	NULL
the	NULL
proenkephalin	NULL
promoter	NULL
is	NULL
specific	NULL
for	NULL
activated	NULL
T	NULL
cells	NULL
.	NULL

A	NULL
similar	NULL
situation	NULL
exists	NULL
for	NULL
the	NULL
promoter	NULL
of	NULL
the	NULL
lymphokine	NULL
IL-2	NULL
,	NULL
which	NULL
is	NULL
activated	NULL
through	NULL
a	NULL
«	NULL
B-like	NULL
regulatory	NULL
sequence	NULL
only	NULL
in	NULL
activated	NULL
T	NULL
cells	NULL
(	NULL
25	NULL
)	NULL
.	NULL

Notably	NULL
,	NULL
both	NULL
in	NULL
the	NULL
proenkephalin	NULL
(	NULL
this	NULL
study	NULL
)	NULL
and	NULL
in	NULL
the	NULL
IL-2	NULL
promoter	NULL
(	NULL
14a	NULL
)	NULL
,	NULL
the	NULL
major	NULL
DNA-binding	NULL
activity	NULL
to	NULL
the	NULL
«	NULL
B-like	NULL
sites	NULL
was	NULL
the	NULL
homodimeric	NULL
form	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
(	NULL
Fig	NULL
.	NULL

3a	NULL
and	NULL
4	NULL
)	NULL
.	NULL

Consistent	NULL
with	NULL
this	NULL
was	NULL
a	NULL
competition	NULL
experiment	NULL
showing	NULL
that	NULL
the	NULL
IL-2	NULL
<	NULL
B-like	NULL
sequence	NULL
and	NULL
the	NULL
B2	NULL
site	NULL
of	NULL
proenkephalin	NULL
are	NULL
bound	NULL
by	NULL
the	NULL
same	NULL
protein	NULL
(	NULL
Fig	NULL
.	NULL

3b	NULL
)	NULL
.	NULL

However	NULL
,	NULL
as	NULL
both	NULL
sequences	NULL
were	NULL
also	NULL
recognized	NULL
,	NULL
albeit	NULL
with	NULL
lower	NULL
affinity	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
)	NULL
,	NULL
by	NULL
the	NULL
heterotetrameric	NULL
form	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
,	NULL
it	NULL
is	NULL
difficult	NULL
to	NULL
determine	NULL
which	NULL
of	NULL
the	NULL
two	NULL
forms	NULL
of	NULL
the	NULL
factor	NULL
is	NULL
responsible	NULL
for	NULL
the	NULL
T-cell-specific	NULL
activation	NULL
of	NULL
these	NULL
two	NULL
promoters	NULL
.	NULL

But	NULL
the	NULL
ubiquity	NULL
of	NULL
NF-kB	NULL
,	NULL
as	NULL
opposed	NULL
to	NULL
the	NULL
T-cell	NULL
specificity	NULL
of	NULL
the	NULL
«	NULL
B-like	NULL
site-mediated	NULL
proenkephalin	NULL
and	NULL
IL-2	NULL
promoter	NULL
function	NULL
,	NULL
argues	NULL
that	NULL
there	NULL
might	NULL
be	NULL
yet	NULL
another	NULL
T-cell-specific	NULL
factor	NULL
which	NULL
participates	NULL
with	NULL
(	NULL
or	NULL
modulates	NULL
)	NULL
NF-kB	NULL
to	NULL
activate	NULL
these	NULL
promoters	NULL
.	NULL

One	NULL
possibility	NULL
is	NULL
that	NULL
the	NULL
``	NULL
naked	NULL
``	NULL
homodimeric	NULL
form	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
that	NULL
binds	NULL
tighter	NULL
to	NULL
the	NULL
B2	NULL
site	NULL
of	NULL
the	NULL
proenkephalin	NULL
promoter	NULL
is	NULL
the	NULL
target	NULL
for	NULL
such	NULL
a	NULL
T-cell-specific	NULL
interaction	NULL
.	NULL

ACKNOWLEDGMENTS	NULL
We	NULL
thank	NULL
Michael	NULL
Karin	NULL
for	NULL
communicating	NULL
results	NULL
before	NULL
publication	NULL
and	NULL
also	NULL
,	NULL
together	NULL
with	NULL
Michael	NULL
Walker	NULL
,	NULL
Rafael	NULL
Malach	NULL
,	NULL
and	NULL
members	NULL
of	NULL
our	NULL
laboratory	NULL
,	NULL
for	NULL
helpful	NULL
discussions	NULL
and	NULL
for	NULL
comments	NULL
on	NULL
this	NULL
report	NULL
.	NULL

We	NULL
also	NULL
thank	NULL
Rona	NULL
Levin	NULL
and	NULL
Malka	NULL
Kopelowitz	NULL
for	NULL
typing	NULL
the	NULL
manuscript	NULL
.	NULL

This	NULL
work	NULL
was	NULL
supported	NULL
by	NULL
Public	NULL
Health	NULL
Service	NULL
grant	NULL
1	NULL
ROL	NULL
NS28651-01	NULL
from	NULL
the	NULL
National	NULL
Institutes	NULL
of	NULL
Health	NULL
and	NULL
by	NULL
grants	NULL
from	NULL
the	NULL
Israel-American	NULL
Binational	NULL
Science	NULL
Foundation	NULL
,	NULL
the	NULL
Center	NULL
for	NULL
Neurosciences	NULL
at	NULL
the	NULL
Weizmann	NULL
Institute	NULL
of	NULL
Science	NULL
,	NULL
and	NULL
the	NULL
Kekst	NULL
and	NULL
Yeda	NULL
Foundations	NULL
(	NULL
to	NULL
Y.C	NULL
.	NULL
)	NULL

.	NULL

Y.C	NULL
.	NULL

has	NULL
received	NULL
an	NULL
Israel	NULL
Cancer	NULL
Research	NULL
Fund	NULL
career	NULL
development	NULL
award	NULL
.	NULL

REFERENCES	NULL
1	NULL
.	NULL

Akil	NULL
,	NULL
H.	NULL
,	NULL
S.	NULL
J.	NULL
Watson	NULL
,	NULL
E.	NULL
Young	NULL
,	NULL
M.	NULL
E.	NULL
Lewis	NULL
,	NULL
H.	NULL
Khachaturian	NULL
,	NULL
and	NULL
M.	NULL
Walker	NULL
.	NULL

1984	NULL
.	NULL

Endogenous	NULL
opioids	NULL
:	NULL
biology	NULL
and	NULL
func-tion	NULL
.	NULL

Annu	NULL
.	NULL

Rev	NULL
.	NULL

Neurosci	NULL
.	NULL

7:223-255	NULL
.	NULL

1022	NULL
10	NULL
.	NULL

11	NULL
.	NULL

12	NULL
.	NULL

13	NULL
.	NULL

14	NULL
.	NULL

RATTNER	NULL
ET	NULL
AL	NULL
.	NULL

.	NULL

Atchison	NULL
,	NULL
M.	NULL
L.	NULL
,	NULL
and	NULL
R.	NULL
P.	NULL
Perry	NULL
.	NULL

1987	NULL
.	NULL

The	NULL
role	NULL
of	NULL
the	NULL
x	NULL
enhancer	NULL
and	NULL
its	NULL
binding	NULL
factor	NULL
NF-kB	NULL
in	NULL
the	NULL
developmental	NULL
regulation	NULL
of	NULL
x	NULL
gene	NULL
transcription	NULL
.	NULL

Cell	NULL
48:121-128.	NULL
.	NULL

Baeuerle	NULL
,	NULL
P.	NULL
A.	NULL
,	NULL
and	NULL
D.	NULL
Baltimore	NULL
.	NULL

1988	NULL
.	NULL

IxB	NULL
:	NULL
a	NULL
specific	NULL
inhibitor	NULL
of	NULL
the	NULL
transcription	NULL
factor	NULL
.	NULL

Science	NULL
242:540-546.	NULL
.	NULL

Baeuverle	NULL
,	NULL
P.	NULL
A.	NULL
,	NULL
and	NULL
D.	NULL
Baltimore	NULL
.	NULL

1989	NULL
.	NULL

A	NULL
65-kD	NULL
subunit	NULL
of	NULL
active	NULL
NF-	NULL
«	NULL
B	NULL
is	NULL
required	NULL
for	NULL
inhibition	NULL
of	NULL
NF-xB	NULL
by	NULL
IxB	NULL
.	NULL

Genes	NULL
Dev	NULL
.	NULL

3:1689-1698.	NULL
.	NULL

Comb	NULL
,	NULL
M.	NULL
,	NULL
N.	NULL
C.	NULL
Girnberg	NULL
,	NULL
A.	NULL
Seasholtz	NULL
,	NULL
E.	NULL
Herbert	NULL
,	NULL
and	NULL
H.	NULL
M.	NULL
Goodman	NULL
.	NULL

1986	NULL
.	NULL

A	NULL
cyclic	NULL
AMP-	NULL
and	NULL
phorbol	NULL
ester-inducible	NULL
DNA	NULL
element	NULL
.	NULL

Nature	NULL
(	NULL
London	NULL
)	NULL
323:353-356.	NULL
.	NULL

Comb	NULL
,	NULL
M.	NULL
,	NULL
N.	NULL
Mermod	NULL
,	NULL
S.	NULL
E.	NULL
Hymen	NULL
,	NULL
J.	NULL
Pearlberg	NULL
,	NULL
E.	NULL
M.	NULL
Ross	NULL
,	NULL
and	NULL
H.	NULL
M.	NULL
Goodman	NULL
.	NULL

1988	NULL
.	NULL

Proteins	NULL
bound	NULL
at	NULL
adjacent	NULL
DNA	NULL
elements	NULL
act	NULL
synergistically	NULL
to	NULL
regulate	NULL
human	NULL
proenkephalin	NULL
cAMP	NULL
inducible	NULL
transcription	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

7:3793-3805.	NULL
.	NULL

Cross	NULL
,	NULL
S.	NULL
L.	NULL
,	NULL
N.	NULL
F.	NULL
Halden	NULL
,	NULL
M.	NULL
Lenardo	NULL
,	NULL
and	NULL
W.	NULL
J.	NULL
Leonard	NULL
.	NULL

1989	NULL
.	NULL

Functionally	NULL
distinct	NULL
NF-kB	NULL
binding	NULL
sites	NULL
in	NULL
the	NULL
immunoglobulin	NULL
k	NULL
and	NULL
IL-2	NULL
receptor	NULL
alpha	NULL
chain	NULL
genes	NULL
.	NULL

Science	NULL
244	NULL
:	NULL
466-469.	NULL
.	NULL

Edbrook	NULL
,	NULL
M.	NULL
E.	NULL
,	NULL
D.	NULL
W.	NULL
Burt	NULL
,	NULL
S.	NULL
K.	NULL
Cheshire	NULL
,	NULL
and	NULL
P.	NULL
Woo	NULL
.	NULL

1989	NULL
.	NULL

Identification	NULL
of	NULL
cis-acting	NULL
sequences	NULL
responsible	NULL
for	NULL
phorbol	NULL
ester	NULL
induction	NULL
of	NULL
human	NULL
serum	NULL
amyloid	NULL
A	NULL
gene	NULL
expression	NULL
via	NULL
a	NULL
nuclear	NULL
factor	NULL
kB-like	NULL
transcription	NULL
factor	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

9:1908-1916.	NULL
.	NULL

Fried	NULL
,	NULL
M.	NULL
,	NULL
and	NULL
D.	NULL
M.	NULL
Crothers	NULL
.	NULL

1981	NULL
.	NULL

Equilibria	NULL
and	NULL
kinetics	NULL
of	NULL
Lac	NULL
repressor	NULL
operator	NULL
interactions	NULL
by	NULL
polyacrylamide	NULL
gel	NULL
elec-trophoresis	NULL
.	NULL

Nucleic	NULL
Acids	NULL
Res	NULL
.	NULL

9:6505-6525	NULL
.	NULL

Garner	NULL
,	NULL
M.	NULL
M.	NULL
,	NULL
and	NULL
A.	NULL
Revzin	NULL
.	NULL

1981	NULL
.	NULL

A	NULL
gel	NULL
electrophoresis	NULL
method	NULL
for	NULL
quantifying	NULL
the	NULL
binding	NULL
of	NULL
proteins	NULL
to	NULL
specific	NULL
DNA	NULL
regions	NULL
:	NULL
application	NULL
to	NULL
components	NULL
of	NULL
the	NULL
E.	NULL
coli	NULL
lactose	NULL
operon	NULL
regulatory	NULL
system	NULL
.	NULL

Nucleic	NULL
Acids	NULL
Res	NULL
.	NULL

9:3047-3060	NULL
.	NULL

Ghosh	NULL
,	NULL
S.	NULL
,	NULL
A.	NULL
M.	NULL
Gifford	NULL
,	NULL
L.	NULL
R.	NULL
Riviere	NULL
,	NULL
P.	NULL
Tempst	NULL
,	NULL
G.	NULL
P.	NULL
Nolan	NULL
,	NULL
and	NULL
D.	NULL
Baltimore	NULL
.	NULL

1990	NULL
.	NULL

Cloning	NULL
of	NULL
the	NULL
p50	NULL
DNA	NULL
binding	NULL
subunit	NULL
of	NULL
NF-kB	NULL
:	NULL
homology	NULL
to	NULL
rel	NULL
and	NULL
dorsal	NULL
.	NULL

Cell	NULL
62:1019-1029	NULL
.	NULL

Gorman	NULL
,	NULL
C.	NULL
M.	NULL
,	NULL
L.	NULL
F.	NULL
Moffat	NULL
,	NULL
and	NULL
B.	NULL
H.	NULL
Howard	NULL
.	NULL

1982	NULL
.	NULL

Recombinant	NULL
genomes	NULL
which	NULL
express	NULL
chloramphenicol	NULL
acetyltransferase	NULL
in	NULL
mammalian	NULL
cells	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

2:1044-1051	NULL
.	NULL

GrosschedI	NULL
,	NULL
R.	NULL
,	NULL
and	NULL
D.	NULL
Baltimore	NULL
.	NULL

1985	NULL
.	NULL

Cell-type	NULL
specificity	NULL
of	NULL
immunoglobulin	NULL
gene	NULL
expression	NULL
is	NULL
regulated	NULL
by	NULL
at	NULL
least	NULL
three	NULL
DNA	NULL
sequence	NULL
elements	NULL
.	NULL

Cell	NULL
41:885-897	NULL
.	NULL

Hoyos	NULL
,	NULL
B.	NULL
,	NULL
D.	NULL
W.	NULL
Ballard	NULL
,	NULL
E.	NULL
Bohnlein	NULL
,	NULL
M.	NULL
Sickevitz	NULL
,	NULL
and	NULL
W.	NULL
C.	NULL
Greene	NULL
.	NULL

1989	NULL
.	NULL

Kappa	NULL
B-specific	NULL
DNA	NULL
binding	NULL
proteins	NULL
:	NULL
role	NULL
in	NULL
the	NULL
regulation	NULL
of	NULL
human	NULL
interleukin	NULL
2	NULL
gene	NULL
expression	NULL
.	NULL

Science	NULL
244:457-460	NULL
.	NULL

14a.Karin	NULL
,	NULL
M.	NULL
Personal	NULL
communication	NULL
.	NULL

15	NULL
.	NULL

16	NULL
.	NULL

17	NULL
.	NULL

Kieran	NULL
,	NULL
M.	NULL
,	NULL
V.	NULL
Blank	NULL
,	NULL
F.	NULL
Logeat	NULL
,	NULL
J.	NULL
Vandekerckhove	NULL
,	NULL
F.	NULL
Lottspe-ich	NULL
,	NULL
O	NULL
.	NULL

Le	NULL
Bail	NULL
,	NULL
M.	NULL
B	NULL
.	NULL

Urban	NULL
,	NULL
P.	NULL
Kourilsky	NULL
,	NULL
P.	NULL
A.	NULL
Baeuerie	NULL
,	NULL
and	NULL
A.	NULL
Israel	NULL
.	NULL

1990	NULL
.	NULL

The	NULL
DNA	NULL
binding	NULL
subunit	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
is	NULL
identical	NULL
to	NULL
factor	NULL
KBF1	NULL
and	NULL
homologous	NULL
to	NULL
the	NULL
rel	NULL
oncogene	NULL
product	NULL
.	NULL

Cell	NULL
62:1007-1018	NULL
.	NULL

Korner	NULL
,	NULL
M.	NULL
,	NULL
A.	NULL
Rattner	NULL
,	NULL
F.	NULL
Mauxion	NULL
,	NULL
R.	NULL
Sen	NULL
,	NULL
and	NULL
Y.	NULL
Citri	NULL
.	NULL

1989	NULL
.	NULL

A	NULL
brain-specific	NULL
transcription	NULL
activator	NULL
.	NULL

Neuron	NULL
3:563-572	NULL
.	NULL

Lenardo	NULL
,	NULL
M.	NULL
,	NULL
C.-M	NULL
.	NULL

Fan	NULL
,	NULL
T.	NULL
Maniatis	NULL
,	NULL
and	NULL
D.	NULL
Baltimore	NULL
.	NULL

1989	NULL
.	NULL

The	NULL
involvement	NULL
of	NULL
NF-kB	NULL
in	NULL
B-interferon	NULL
gene	NULL
regulation	NULL
18	NULL
.	NULL

19	NULL
.	NULL

20	NULL
.	NULL

21	NULL
.	NULL

22	NULL
.	NULL

23	NULL
.	NULL

24	NULL
.	NULL

25	NULL
.	NULL

26	NULL
.	NULL

27	NULL
.	NULL

28	NULL
.	NULL

29	NULL
.	NULL

30	NULL
.	NULL

31	NULL
.	NULL

33	NULL
.	NULL

Mor	NULL
.	NULL

CELL	NULL
.	NULL

BioL	NULL
.	NULL

reveals	NULL
its	NULL
role	NULL
as	NULL
widely	NULL
inducible	NULL
mediator	NULL
of	NULL
signal	NULL
transduc-tion	NULL
.	NULL

Cell	NULL
57:287-294	NULL
.	NULL

Lenardo	NULL
,	NULL
M.	NULL
,	NULL
A.	NULL
Kuang	NULL
,	NULL
A.	NULL
Gifford	NULL
,	NULL
and	NULL
D.	NULL
Baltimore	NULL
.	NULL

1988	NULL
.	NULL

NF-kB	NULL
protein	NULL
purification	NULL
from	NULL
bovine	NULL
spleen	NULL
:	NULL
nucleotide	NULL
stimulation	NULL
and	NULL
binding	NULL
site	NULL
specificity	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
85:8825-8829	NULL
.	NULL

Lenardo	NULL
,	NULL
M.	NULL
,	NULL
J.	NULL
W.	NULL
Pierce	NULL
,	NULL
and	NULL
D.	NULL
Baltimore	NULL
.	NULL

1987	NULL
.	NULL

Protein-binding	NULL
sites	NULL
in	NULL
Ig	NULL
gene	NULL
enhancers	NULL
determine	NULL
transcriptional	NULL
activity	NULL
and	NULL
inducibility	NULL
.	NULL

Science	NULL
236:1573-1577	NULL
.	NULL

Morinaga	NULL
,	NULL
Y.	NULL
,	NULL
T.	NULL
Franceshini	NULL
,	NULL
S.	NULL
Inouye	NULL
,	NULL
and	NULL
M.	NULL
Inouye	NULL
.	NULL

1984	NULL
.	NULL

Improvement	NULL
of	NULL
oligonucleotide-directed	NULL
site-specific	NULL
mutagen-esis	NULL
using	NULL
double-stranded	NULL
plasmid	NULL
DNA	NULL
.	NULL

Bio/Technology	NULL
2:636-639	NULL
.	NULL

Nabel	NULL
,	NULL
G.	NULL
,	NULL
and	NULL
D.	NULL
Baltimore	NULL
.	NULL

1987	NULL
.	NULL

An	NULL
inducible	NULL
transcription	NULL
factor	NULL
activates	NULL
expression	NULL
of	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
in	NULL
T	NULL
cells	NULL
.	NULL

Nature	NULL
(	NULL
London	NULL
)	NULL
326:711-713	NULL
.	NULL

Nelsen	NULL
,	NULL
B.	NULL
,	NULL
L.	NULL
Hellman	NULL
,	NULL
and	NULL
R.	NULL
Sen.	NULL
1988	NULL
.	NULL

The	NULL
NF-	NULL
«	NULL
B	NULL
binding	NULL
site	NULL
mediates	NULL
phorbol	NULL
ester-inducible	NULL
transcription	NULL
in	NULL
nonlym-phoid	NULL
cells	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

8:3526-3531	NULL
.	NULL

Osborn	NULL
,	NULL
L.	NULL
,	NULL
S.	NULL
Kunkel	NULL
,	NULL
and	NULL
G.	NULL
S.	NULL
Nabel	NULL
.	NULL

1989	NULL
.	NULL

Tumor	NULL
necrosis	NULL
factor	NULL
a	NULL
and	NULL
interleukin	NULL
1	NULL
stimulate	NULL
the	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
enhancer	NULL
by	NULL
activation	NULL
of	NULL
the	NULL
nuclear	NULL
factor	NULL
kB	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
86:2336-2340	NULL
.	NULL

Pierce	NULL
,	NULL
J.	NULL
W.	NULL
,	NULL
M.	NULL
Lenardo	NULL
,	NULL
and	NULL
D.	NULL
Baltimore	NULL
.	NULL

1988	NULL
.	NULL

Oligonucleotide	NULL
that	NULL
binds	NULL
nuclear	NULL
factor	NULL
NF-	NULL
«	NULL
B	NULL
acts	NULL
as	NULL
lymphoid-specific	NULL
and	NULL
inducible	NULL
enhancer	NULL
element	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
85:1482-1486	NULL
.	NULL

Radler-Pohl	NULL
,	NULL
A.	NULL
,	NULL
I.	NULL
Pfeuffer	NULL
,	NULL
M.	NULL
Karin	NULL
,	NULL
and	NULL
E.	NULL
Serfling	NULL
.	NULL

New	NULL
Biol	NULL
.	NULL

,	NULL
in	NULL
press	NULL
.	NULL

Rosen	NULL
,	NULL
H.	NULL
,	NULL
O.	NULL
Behar	NULL
,	NULL
O.	NULL
Abramsky	NULL
,	NULL
and	NULL
H.	NULL
Ovadia	NULL
.	NULL

1989	NULL
.	NULL

Regulated	NULL
expression	NULL
of	NULL
proenkephalin	NULL
A	NULL
in	NULL
normal	NULL
lymphocytes	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

143	NULL
;	NULL
3703-3707	NULL
.	NULL

Rosen	NULL
,	NULL
H.	NULL
,	NULL
J.	NULL
Douglass	NULL
,	NULL
and	NULL
E.	NULL
Herbert	NULL
.	NULL

1984	NULL
.	NULL

Isolation	NULL
and	NULL
characterization	NULL
of	NULL
the	NULL
rat	NULL
proenkephalin	NULL
gene	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

259:14309-14313	NULL
.	NULL

Sen	NULL
,	NULL
R.	NULL
,	NULL
and	NULL
D.	NULL
Baltimore	NULL
.	NULL

1986	NULL
.	NULL

Multiple	NULL
nuclear	NULL
factors	NULL
interact	NULL
with	NULL
the	NULL
immunoglobulin	NULL
enhancer	NULL
sequences	NULL
.	NULL

Cell	NULL
46:705-716	NULL
.	NULL

Sen	NULL
,	NULL
R.	NULL
,	NULL
and	NULL
D.	NULL
Baltimore	NULL
.	NULL

1986	NULL
.	NULL

Inducibility	NULL
of	NULL
k	NULL
immunoglobulin	NULL
enhancer-binding	NULL
protein	NULL
NF-	NULL
«	NULL
B	NULL
by	NULL
a	NULL
posttranslational	NULL
mechanism	NULL
.	NULL

Cell	NULL
47:921-928	NULL
.	NULL

Visvanathan	NULL
,	NULL
K.	NULL
V.	NULL
,	NULL
and	NULL
S.	NULL
Goodbourn	NULL
.	NULL

1989	NULL
.	NULL

Double-stranded	NULL
RNA	NULL
activates	NULL
binding	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
to	NULL
an	NULL
inducible	NULL
element	NULL
in	NULL
the	NULL
human	NULL
B-interferon	NULL
promoter	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

8:1129-1138	NULL
.	NULL

Zabel	NULL
,	NULL
U.	NULL
,	NULL
and	NULL
P.	NULL
A.	NULL
Baeuerle	NULL
.	NULL

1990	NULL
.	NULL

Purified	NULL
human	NULL
IxB	NULL
can	NULL
rapidly	NULL
dissociate	NULL
the	NULL
complex	NULL
of	NULL
the	NULL
NF-	NULL
«	NULL
B	NULL
transcription	NULL
factor	NULL
with	NULL
its	NULL
cognate	NULL
DNA	NULL
.	NULL

Cell	NULL
61:255-265.	NULL
.	NULL

Zabel	NULL
,	NULL
U.	NULL
,	NULL
R.	NULL
Schreck	NULL
,	NULL
and	NULL
P.	NULL
A.	NULL
Baeuerie	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

,	NULL
in	NULL
press	NULL
.	NULL

Zurawaski	NULL
,	NULL
G.	NULL
,	NULL
M.	NULL
Benedik	NULL
,	NULL
B.	NULL
J.	NULL
Komb	NULL
,	NULL
J.	NULL
S.	NULL
Abrams	NULL
,	NULL
S.	NULL
M.	NULL
Zurawaski	NULL
,	NULL
and	NULL
F.	NULL
D.	NULL
Lee	NULL
.	NULL

1986	NULL
.	NULL

Activation	NULL
of	NULL
mouse	NULL
T-helper	NULL
cells	NULL
includes	NULL
abundant	NULL
proenkephalin	NULL
mRNA	NULL
synthesis	NULL
.	NULL

Science	NULL
232:772-775	NULL
.	NULL

